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Nitric oxide (NO) is an important modulator of physiological and pathophysiological 
function of the cardiovascular, neuronal, and immune systems. The overproduction of 
NO by nitric oxide synthase (NOS) has been implicated in many diseases therefore 
inhibitors of NOS may be useful as therapeutic agents. 
Previous work from our laboratory postulated that the diphenyl moiety of lead 
compound I would interact with the region adjacent to the guanidine binding site 
(RegG). It was hypothesized that structural modification made on one of the phenyl 
rings of I may improve the binding affinity. The objectives of this project were to 
synthesize a series of compounds MK-I with one of the phenyl rings of I replaced by 
various ring systems, to synthesize a series of compounds MK-II with the 
introduction of a polar side chain with polar functional groups at the meta-position of 
one of the phenyl rings, to screen library MK-I and MK-II compounds against the 
three isoforms of NOS and to screen a series of guanidino-containing heterocyclic 
compounds against the nNOS isoform. 
A series of amines were synthesized with yields of 71 to 99% for coupling with S-
methyl-N-nitroisothiourea (SMNNITU) to form library MK-I and MK-II compounds. 
The yields obtained for library MK-I and MK-II compounds ranged from 48 to 75% 
and 37 to 47% respectively. Library MK-I and MK-II compounds were screened for 
their inhibitory activities against the three isoforms of NOS at 100µM. The pyridinyl 
ring with the nitrogen at the para position (MK-I-03) gave moderate inhibition of 
36% for nNOS isoform for library MK-I as compared to the nitrogen at meta- and 
ortho- positions. As the cyclo-hydrocarbon ring size increased (from cyclopropane to 
cyclopentane), the inhibition for nNOS isoform also increased. The percent inhibition 
 vi 
for nNOS isoform was found to decrease to 29% when R1 was cyclohexane (MK-I-
07).   
Both MK-I-08 and MK-I-09 were nNOS selective. MK-I-08 had a naphthalene 
group which may be responsible for hydrophobic interaction at the active site, thereby 
giving rise to a high inhibition of 83%. MK-I-09 had a thiophene group which may be 
able to fit into the active site pocket thereby causing a strong inhibiton of 120% with 
respect to the positive control (100%), L-NG-nitro-arginine (L-NNA). 
Another library of guanidino-containing hetereocycles was screened for their 
inhibitory activities against the nNOS at 100µM. Compound X gave the highest 
inhibition of 44% among the guanidino-containing hetereocycles screened. This could 
be due to stronger interactions (e.g. hydrogen bonding) of the sulphur with the active 
site.  
From the screening results, it could be seen that the majority of library MK-I 
compounds, MK-II compounds and the guanidino-containing heterocycles gave some 
inhibition against the nNOS isoform. Unfortunately there was not enough data to 
prove that these compounds had better inhibitory actions as compared to I as they 
were screened only at 100µM. Futher screenings of the respective compounds could 
be done (i.e. respective IC50), for a more conclusive comparison between the results in 
order to achieve the objectives completely.  
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CHAPTER 1: INTRODUCTION 
 
1.1 Chemistry of Nitric Oxide 
Nitric oxide (NO) is a colorless gas at room temperature and pressure. The NO 
molecule possesses an unpaired pi antibonding electron which renders it paramagnetic 
and partially cancels the effect of the pi-bonding electrons. Even though NO is a 
radical, it does not have a strong tendency to dimerize.[1] NO remains in the 
monomeric form at standard temperature and pressure as the overall bonding does not 
increase when two NO molecules interact. NO is thermodynamically unstable at 25oC 
and 1 atm.[1] The decomposition of NO is kinetically hindered even though it is 
thermodynamically unstable. Under pressure and in the range of 30 to 50oC, NO 
readily decomposes and disproportionates to form N2O and NO2 (Scheme 1).[1]  
 
3NO N2O  +  NO2
 
 
Scheme 1 Disproportionation of NO to form N2O and NO2 
 
The nitrosonium ion (NO+) is formed when the pi antibonding electron in the pi* 
orbital of NO is lost. The oxidation state of nitrogen in NO+ is +3. The bond length 
decreases by 0.09 Å and the bond is therefore stronger in NO+ than in NO because the 
electron removed is from the antibonding orbital.[1] The NO+ ion is isoelectronic with 
CO and N2, where both contain strong triple bonds. The NO+ ion has been isolated in 
a variety of salts such as nitrosonium hydrogensulfate (+NO.HSO4-) nitrosonium 
perchlorate (+NO.ClO4-) and nitrosonium tetrafluoroborate (+NO.BF-).[1]  
NO is not a nitrosating agent by itself and it is readily reduced and oxidized but the 
roles of the reduced and oxidized products are limited physiologically. The major 
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physiological nitrating agent is the reactive nitric oxide species (RSNO) which serves 
as NO+ donor (Scheme 2).[2]  
 














Scheme 2 The autoxidation of NO 
 
The specific chemical reactions of NO with biological targets are catergorized into 
direct and indirect effects. Reactions between NO and specific biological molecules 
are termed direct effects whereas reactions of NO with RSNO from NO autoxidation 
with various biological targets are termed indirect effects.[3] The formation of RSNO is 
dependent on [NO] and [O2]. NO becomes the limiting reagent since [O2] is high in 
physiological systems. The RSNO formation has a second order kinetic dependency on 
[NO].[3] The second-order dependence of NO makes the half-life of NO in aqueous 
solution proportional to its concentration. The autoxidation increase exponentially, 
generating higher fluxes of RSNO as the NO concentration increases.[4] The direct and 
indirect effects are partitioned by the second-order nature of the autoxidation reaction. 
The possible chemical reactions are limited by the selectivity of NO and the 
occurrence of these reactions is limited by the concentration dependence of NO for 
formation of RSNO. [3] Therefore the direct biological effects of NO are attributed to 
NO itself whereas the indirect biological effects are attributed to the oxidative 
products of NO (mainly RSNO).[3] 
 3 
The results of the reactions of NO with metals and radicals are the direct biological 
effects of NO. The formation of metal-nitrosyl adducts results from the reaction of 
NO with some transition metal complexes such as Fe2+ and Fe3+.[3, 5] The reaction 
between NO and heme cofactors within the protein is important in the regulation of 
guanylate cyclase activity. The conversion of guanosine 5’-triphosphate (GTP) to 
guanosine 3’, 5’-cyclic monophosphate (cGMP) is stimulated as shown by the binding 
of NO to the heme moiety of the guanylate cyclase protein.[6] NO also reacts with 
cytochrome P450 and metalloproteins (oxyhemoglobin or oxymyoglobin).[7] NO is 
able to reversibly inhibit the cytochrome P450 enzymes.[8] The mechanism of this 
nitrosyl formation is similar to the mechanism of CO inhibition where there is the 
formation of the Fe-NO bond which prevents the binding of O2.[8] 
Scheme 3 shows the redox relationship of NO with other nitrogen oxides.[9] It can be 
seen from Scheme 3 that NO is in a central and unique position in the redox scheme. 
Hydroxylamine is generated from a two-electron oxidation of ammonia (NH3) and 
further two-electron oxidation of hydroxylamine generates nitroxyl (HNO). NO is 
then generated by a single-electron oxidation of HNO, which is further oxidized (one-
electron oxidation) to form nitrite (NO2-). 
 
N(+5)O3- N(+3)O2- N(+2)O HN(+1)O N(-1)H2OH N(-3)H3
+ 2e-
- 2e-
+ 2e- + 2e-
- 2e- - 2e-
+ 1e- + 1e-
- 1e-- 1e-
nitrate nitrite nitric oxide nitroxyl hydroxylamine ammonia
 
 
Scheme 3 Nitrogen oxides redox scheme 
(The formal nitrogen oxidation state is represented in the parantheses) 
 
NO, being a fairly unreactive radical species is capable of reacting with other 
radicals.[3, 10, 11] Radical-radical addition is therefore the most likely route for any 
 4 
potential direct effects of nitric oxide as it is highly reactive towards other radicals. 
The most common and biological significant radical is molecular oxygen (O2).[9] NO 
reacts with O2 in the gas phase to form nitrogen dioxide (NO2). In aqueous aerobic 
solutions, the decomposition of NO gives NO2 as the immediate product. The NO2 
generated under these conditions does not decompose to give equal amounts of NO2- 
and NO3-. This is because the NO2 generated from the autoxidation of NO reacts with 
another molecule of NO to give dinitrogen trioxide (N2O3). The N2O3 decomposes in 
H2O to give NO2- exclusively.[12, 13] 
The chemistry of NO in aqueous aerobic systems is therefore complex.[13-15] There is a 
possibility that several nitrogen oxide species such as NO, .OONO, NO2, (NO)2, N2O3, 
NO2- and NO3-, can exist in solution simultaneously. NO2 is a paramagnetic radical 
species and monomeric NO2 is a brown gas and is in equilibrium with N2O4, which is 
the dimeric form and is colorless.[9] NO2 exists primarily in the dimeric form below its 
boiling point of 21oC.[9] NO should be stable indefinitely under anaerobic conditions 
since O2 is the ultimate oxidant in the formation of the oxidized NO species in 
aqueous solutions.[12]  
Together with O2, NO can also react with the one-electron reduction product of O2, 
which is superoxide (O2-). O2- is also a ubiquitous biological radical as it possesses an 
unpaired electron. The reaction of NO with O2- proceeds at a near-diffusion controlled 
rate where k = 6.7 × 109 M-1.s-1,[16] implying that it is a very fast reaction. 
Peroxynitrite (-OONO) is the product formed from the reaction of NO with O2-. The 
anion product, –OONO, is stable and has a pKa of 6.8. The protonation of –OONO to 















Scheme 4 Decomposition of HOONO to NO3- 
 
–OONO can carry out aromatic hydroxylations and one- or two- electron oxidation of 
nucleophiles, resulting in many products that are indistinguishable form those seen 
with other oxidants such as hydroxyl radical and nitrogen dioxide. –OONO however 
nitrates phenolic compounds (tyrosine residues in proteins) readily and has been 
detected in a number of human tissues using a qualitative immunological approach as 
well as quantitative methods such as high-performance liquid chromatography.[18, 19] 
Under mildly acidic conditions, –OONO could conceivably be formed in vivo by the 
reaction of NO2- with hydrogen peroxide. This pathway is inefficient as the hydrogen 
peroxide would be competing with much higher concentrations of thiols, amines and 
water. A variety of biological molecule has been showed to be oxidized by –OONO 
and it may therefore be responsible for certain types of NO-mediated toxicity.[17] 
The relationship between direct and indirect biological effects of NO is [NO] 
dependence. Direct effects will come into play at lower [NO] whereas indirect effects 
will be important at high [NO].[3] The [NO] dilutes rapidly as NO diffuses away from 
the site of origin, thereby protecting it from the reaction with O2. This implies that a 
relatively localized area occurs for the indirect effects.[4] The reactivity, selectivity 
and diffusibility of NO regulate the overall in vivo effect of NO. NO is produced in 
vivo under two modes: constitutive and inducible modes respectively. In the 
constitutive mode, NO is released at micromolar levels in the microenvironment of 
the cell. Whereas for the inducible mode, NO is generated in large fluxes and is 
associated with the destructive indirect biological effects of NO.[3, 20] 
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1.2 Nitric Oxide and Nitric Oxide Synthase 
NO has been regarded as an atmospheric pollutant and bacterial metabolite till the 
mid-1980s. From then, NO has been implicated in various number of biological 
processes. NO is an important modulator of physiological and pathophysiological 
function of the cardiovascular, neuronal, and immune systems. It is involved as an 
intercellular signal and defensive cytotoxin in the nervous, muscular, cardiovascular, 
and immune systems.[21-23] NO is also involved in the complex mechanism of tissue 
injury by perpetuating the inflammatory process and also even facilitating apoptosis. 
In mammalian cells, NO is synthesized from L-arginine (L-Arg) by a family of 
enzymes called the nitric oxide synthase (NOS).[24] These enzymes catalyze the 
oxidation of L-Arg to give L-citrulline (L-Cit) and NO, with Nω-hydroxy-L-arginine 
(NOH-L-Arg) being formed as an stable intermediate,[22, 25, 26] in this nicotinamide 
adenine dinucleotide phosphate (NADPH) and oxygen (O2) dependent process. NOSs 
are flavohaem enzymes that are active only as dimers. Each monomer has a 
carboxyterminal diflavin-reductase domain and an aminoterminal oxygenase domain 
(Figure 1).  
 
Reductase domain     Oxygenase domain 
N’– NADPH FAD FMN CaM BH4 Haem L-Arg –C’ 
 
Figure 1 Schematic representation of the NOS primary structure with binding sites 
for substrate and cofactors 
 
1.3 Nitric Oxide Synthase Isoforms 
Three NOS isoforms have been identified and they include the: neuronal NOS 
(nNOS), inducible or inflammatory NOS (iNOS), and endothelial NOS (eNOS).[27] 
nNOS is constitutively expressed in disparate cell types, including airway epithelium 
and skeletal muscles.[28-30] eNOS is also found in skeletal muscle, heart, epithelial 
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cells and neurons.[31, 32] iNOS expresses a common inducible gene product in response 
to inflammatory cytokines that was originally characterized in macrophages.[33-35] 
These three distinct isoforms have more than 55% homology between them.[36] The 
three isoforms are produced by different genes with different regulation, localization, 
catalytic properties, and inhibitor sensitivity. Each of them is therefore associated 
with different functions.[37]  
NADPH, flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), (6R)-5, 6, 
7, 8-tetrahydrobiopterin (BH4), and Fe-protoporphyrin IX (heme) are cofactors and 
prosthetic groups utilized by the three isoforms. The nNOS and eNOS also require 
added Ca2+ and calmodulin (CaM) for activity,[31, 38] while the iNOS has tightly bound 
Ca2+ and calmodulin (30-70 nM at resting cellular calcium).[39] Therefore, NOSs are 
classified as either calcium and calmodulin-dependent or independent, due to the 
different affinities of the respective isoforms for calmodulin. NOS activity also 
depends on the reduced state of essential protein thiols.  
The dimerization of the NOS is thought to activate the enzyme by sequestering iron 
and thereby generating high-affinity binding sites for L-Arg and BH4 and allowing 
electron transfer from the reductase-domain flavins to the oxygenase-domain heme.[40, 
41]
 The bound calmodulin is also essential in the dimerization as the activity is 
dependent on it.[31, 38, 39] The electronic correlation of NO synthesis is where the 
calmodulin triggers the electron flow between the reductase and oxygenase domains 
of NOS. 
nNOS is important for neurotransmission and long-term potentiation, but this is not 
apparent in nNOS knockout mice.[42] NO produced by the iNOS in activated 
macrophage cells acts as a cytotoxic agent in normal immune responses. eNOS is 
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responsible for the regulation of smooth muscle relaxation and blood pressure; it also 
inhibits platelet aggregation in the body. 
The three isoforms have identical overall architecture despite the fact that they have 
different localizations. It was reported by Gerber et al. that the ceiling height directly 
above the atom of the heme sites differs, which suggested that the size of the  active 
site decreases in the order nNOS > iNOS > eNOS.[43] NOS bears a striking similarity 
to cytochrome P450 based on the cofactor and prosthetic groups required. The 
mammalian P450 system consists of two proteins: a heme-containing, oxygen-
activating cytochrome P450 protein and an NADPH-binding and FAD- and FMN-
containing P450 reductase protein.[44] As for NOS, its catalysis is carried out only by a 
single protein. The reductase protein of P450 is responsible for supplying electrons to 
cytochrome P450 for the heme-mediated activation of molecular oxygen. It is 
therefore assumed that there are some mechanistic similarities between them since 
both NOS and P450 are hemeproteins which require FAD and FMN and use NADPH 
and O2. [44-46] The heme is responsible for binding and reductively activating 
molecular oxygen as FAD and FMN shuttle electrons from NADPH to it (Figure 
2).[44] From this assumption, where NOS catalysis is mechanistically analogous to 
P450, it was found that L-Arg is initially N-hydroxylated to give the intermediate, 
NOH-L-Arg.[47] 
 
NADPH  FAD  FMN  Heme 
 
Figure 2 NOS Reaction stoichiometry 
 
The enzymatic oxidation of L-Arg produces nitric oxide and L-Cit in stiochiometric 
amounts in a two-step reaction. This reaction involves an overall 5-electron oxidation 
of the guanidinium nitrogen (Scheme 6).[48] The formation of the intermediate, NOH-
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L-Arg, involves a two-electron oxidation supported by one molecule of NADPH. The 
formation of NO and L-Cit in the second step involves the insertion of the second 
oxygen. This is supported by 0.5 NADPH molecules and involves an additional three-
electron oxidation. The nitrogen atom in NO is derived from the guanidine nitrogen of 
L-Arg and the oxygen atom in L-Cit is derived from O2, as showed by isotopic 
labeling studies.[49, 50] The intermediate, NOH-L-Arg,[51, 52] was also confirmed by 





















Scheme 5 NOS catalyzed oxidation of L-Arg 
 
Enzyme uncoupling has been found when the substrate L-Arg is in limiting amount, 
where the monooxygenase function of the enzyme is superseded by an oxidase 
activity with consequent production of O2- and hydrogen peroxide (H2O2).[34, 53, 54] 
The N-terminal catalytic oxygenase domain of NOS binds to heme, the substrate and 
BH
4
; there is a central linker region that binds CaM and a C-terminal electron-
supplying reductase domain with binding sites for FAD, FMN, and NADPH.[44] It is 
noted that there are two major differences between the NOS catalysis and cytochrome 
P450. Firstly, the cofactor BH4 is essential for NO production and is a fundamental 
redox factor in both steps of the catalytic cycle for NOS, whereas for cytochrome 
P450, it does not require BH4
.
 Secondly, the product of NOS catalysis (NO) is an odd-
electron free-radical species whereas typically the products of cytochrome P450 
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catalysis are of even, two-electron species.[55] Since the NOS isoforms catalyze the 
conversion of L-Arg to NO and L-Cit, it is expected that their cofactors and prosthetic 
group requirements will be very similar or even identical.  
The overproduction of NO by nNOS has been implicated in many diseases associated 
with the central nervous system.[56-58] NO being a free radical reacts rapidly with 
superoxide (O2-) in aqueous media to form ONOO-, which is a powerful oxidant that 
can modify proteins and liquids by nitration.[17] NO overproduction by nNOS has 
been associated with neurodegenerative diseases such as Alzheimer’s diseases 
Parkinson’s diseases, strokes and neurotoxicity.[56-58] Because eNOS is important in 
regulating the blood pressure in the body,[59, 60] nNOS inhibitors must not inhibit 
eNOS and selective inhibition of the neuronal isoform is essential for nNOS inhibitors 
to be of therapeutic use.  
 
1.4 NOS Structure and Function 
The first report described that the synthesis of NO by NOS required L-Arg and 
NADPH in the enzymatic reaction which formed the side product L-Cit. NO synthesis 
not only requires these substrates but also four other cofactors as well as CaM.[44-46] 
The intron-exon structure of the human NOS genes is remarkably conserved.[61] This 
suggests that the NOS gene family has evolved from a common ancestor by gene 
duplication and that there is a strong evolutionary pressure for preservation of 
structure and function. A structural organization consistent with the domain structure 
predicted by enzymology studies has been revealed by analysis of the protein 
sequences of the mammalian NOS isoforms. Although the N-terminal regions of the 
NOS isoforms are structurally divergent, they serve a common purpose in the 
regulation of NOS function which is to target subcellular compartments.[62] The NOS 
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activity was not affected when the N-terminal 200 amino acids of nNOS were 
removed. The N-terminal of eNOS is myristylated and mutation of the myristylation 
site converts the enzyme from a predominantly membrane associated enzyme to a 
soluble enzyme.[63] eNOS is also palmitoylated at position Cys15 and/or Cys 26 but it 
is still unclear what contribution this post-translational modification makes to eNOS 
localization.[64] There is no detailed study on whether the N-terminus or any other 
portion of iNOS might be involved in regulating soluble and particulate associations 
described.  
The remainder of the NOS protein sequence is therefore arranged in the following 
way from the N-terminus to the C-terminus: a highly conserved oxygenase domain, a 
calmodulin-recognition sequence and a flavoprotein reductase domain. The N-
terminal to C-terminal arrangement of the oxygenase domain to the reductase domain 
is homologous to the structure of bacterial cytochrome P450.[65] The insertion of a 
calmodulin-recognition sequence between the oxygenase domain and the reductase 
domain is the striking feature of NOS.  
 
1.4.1 NADPH and Oxygen 
The N-oxidation of L-Arg occurs through the generation of an active oxygen species 
with the reduction of molecular oxygen. NADPH is the source of electrons for the 
oxygen reduction and activation, as with other monooxygenase such as flavin 
monooxygenase[66] or cytochrome P450.[67] The overall reaction for cytochrome P450 
is illustrated in Scheme 6: 
 
O2  +  NADPH  +  RH  + H+ H2O +  NADP+ +  ROH
 
 
Scheme 6 Reaction of Cytochrome P450  
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One atom of oxygen is incorporated into the substrate (RH), the other being fully 
reduced to water. Therefore it is very likely that the first oxidation step occurs by the 
reaction shown above to give NOH-L-Arg. The subsequent oxidation of the NOH-L-
Arg intermediate to form NO and L-Cit however, cannot be adequately expressed by 
the above reaction. This is because NO production is an overall odd-electron 
oxidation, whereas the reaction above for the cytochrome P450, it is an even, two 
electron oxidation. The stoichiometric studies done by Stuehr et al.[51] indicated that 
only 0.5 NADPH are utilized in this step, which is consistent with the requisite odd-
electron chemistry of the NOS-mediated conversion of NOH-L-Arg to NO. 
 
1.4.2 Calmodulin 
The first protein reported to show interaction with NOS is CaM.[38] CaM is a small 
acidic protein with approximately 148 amino acids.[68] CaM can affect many different 
cellular functions as it is a ubiquitous, calcium-binding protein that can bind to and 
regulate a multitude of different protein targets. Processes such as inflammation, 
metabolism, apoptosis, muscle contraction, intracellular movement, short-term and 
long-term memory, nerve growth and the immune response are mediated by CaM. 
CaM can have different subcellular locations, including the cytoplasm, within 
organelles, or associated with the plasma or organelle membranes and is expressed in 
many cell types. CaM has been used as a calcium sensor and signal transducer as 
many of the proteins that CaM binds are unable to bind calcium themselves. The 
calcium stores in the endoplasmic reticulum and the sarcoplasmic reticulum can be 
made use of by CaM. Upon binding to calcium, CaM undergoes a conformational 
change, which enables it to bind to specific proteins for a specific response. CaM and 
can undergo post-translational modifications, such as acetylation, methylation, 
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phosphorylation, and proteolytic cleavage, each of which can potentially modulate its 
actions and it can bind up to four calcium ions.[69] 
 CaM binding is the main means for the regulation of eNOS and nNOS as it serves to 
gate the flux of electrons between the reductase and oxygenase domains of NOSs. In 
CaM-free nNOS, electrons from NADPH will load into the flavins and can only 
transfer to the NOS heme iron when CaM binds.[70] This electron transfer occurs 
independently of substrate binding and causes the rapid enzymatic oxidation of 
NADPH in the presence of O2 which is required in order for NO synthesis to occur. 
CaM-binding to human iNOS displays a somewhat greater dependence to Ca2+, 
whereas rat iNOS possesses very high CaM avidity even in the presence of Ca2+ 
chelators. Even so, for practical purposes, it may still be considered Ca2+ independent. 
There are structural changes of NOS induced by CaM and may trigger the 
interdomain electron transfer from CaM binding studies to NOS where there is an 
increase in enzyme tryptophan and flavin fluorescence. CaM binding does not alter 
the ability of the NOS heme iron to bind ligands such as CO or cyanide nor does it 
affect the NOS affinity for its substrate L-Arg.[71] 
It was still unclear for the explanation of activation of nNOS NADPH oxidation, 
superoxide formation and cytochrome c reduction even though it was known that 
CaM causes the flavin-to-heme interdomain electron transfer in NOS. From a 
comparison study done by Abu-Soud et al., they could identify which CaM-dependent 
reactions required interdomain electron transfer to the heme iron.[72]  
  
1.4.3 FAD and FMN 
The FMN domain of NOS can be considered to include about 200 amino acids, 
corresponding to nNOS, and is extended from the calmodulin site towards the C 
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terminus. Three exons of CPR were encoded by this sequence and it corresponds to 
exons 14 – 18 of nNOS, 12 – 16 of eNOS and 13 – 16 of iNOS. It is of significance 
that exon 15 of eNOS and exon 17 of nNOS are unique and are not represented in 
either iNOS or CPR which results in an insertion of approximately 30 amino acids 
with unknown functions.[73] The FAD domain contains the binding sites for both FAD 
and NADPH and is encoded by the terminal nine exons (nNOS) or eight exons (eNOS 
and iNOS) in the NOS genes. The FAD and FMN in the reductase domain of NOS 
accept electrons from NADPH and in turn pass them on to the heme domain.[73] The 
fundamental role of the flavin cofactors is to allow NADPH, (a two-electron donor) to 
donate electrons to heme (a one-electron acceptor) by forming stable semiquinone 
radical intermediates. The electron flow is in the direction NADPH  FAD  FMN, 
as revealed by characterization of FMN-deficient mutants.[74] The electron transfer 
from FAD to FMN is slow in the absence of CaM-Ca2+.[70] The flow of electrons 
between FAD and FMN has been suggested to be the control point where CaM acts. 
The CaM-Ca2+ binding has minimal effect on the redox potential of the flavins and 
the effect of CaM is considered as kinetic.[75]  
 
1.4.4 Heme 
The heme cofactor is present in stoichiometric quantites in nNOS and they are 
required for full catalytic activity.[76-78] The heme in NOS is to bind, reduce and 
activate molecular oxygen in order to generate the high-valent, metal-oxo oxidant. 
Heme-binding ligands such as CO in the presence of NADPH, some arginine analogs 
that ligate heme and imidazoles disrupt NOS activity.[67] The iron-heme environment 
in NOS appears to be similar to that of cytochrome P450 in which the pentavalent 
coordinated heme-iron is ligated axially by a fifth axial ligand, which is the thiolate.[77] 
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Site-directed mutagenesis confirmed the identification of the specific cysteine residue 
that is involved in the heme coordination.[79] It was distinguished in rat nNOS on the 
basis of homology of Cys-415 with cytochromes P450.[80] Another similar site-
directed mutagenesis analysis suggested that the homologous cysteine in eNOS also 
provides the fifth ligand to heme.[81] Every species examined shows that this cysteine 
is actually conserved in all the isoforms of NOS. This cysteine corresponds to Cys-
184 in human eNOS and Cys-200 in human iNOS.[73] Two imidazole molecules have 
been found to bind to each monomer of the murine iNOS heme domain, the heme and 
the arginine binding region of Glu-371.[82, 83] The redox potentials of both hemes are 
similar and they each have a thiolate (cysteine) ligand.[84]  
The role of the heme is to bind, reduce and also to activate O2 to generate the oxidant. 
However, both hemes in the two enzymes have fundamental structural and functional 
differences. Unlike in P450, a tryptophan is structurally hydrogen bonded to the heme 
thiolate ligand in NOS. The NOS catalyses a multi-electron oxidation instead of a 
two-electron one functionally, and two oxidation cycles result from this. The first 
cycle is the formation of NOH-L-Arg (monooxygenase I) and the second cycle 
(monooxygenase II) is to convert NOH-L-Arg to NO (or NO-). In comparison, P450 
reactions require a single cycle and there are no stable intermediates formed.[84]  
 



















Figure 3 Structure of (6R)-5, 6, 7, 8-tetrahydrobiopterin 
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The NOS enzymes are the only heme-containing enzymes that require the cofactor 
BH4 for maximal activation.[27] On the other hand, the exact role of BH4 in NO 
biosynthesis is not yet known. The BH4 binding site is located adjacent to the 
arginine-binding region and also the heme cofactor.[85, 86] Compounds synthesized 
have been identified to interact with the BH4 binding site with different mechanisms. 
They can interact via competition for binding of radiolabelled BH4 to full-length or 
heme domains of NOS, mutual antagonism with BH4 on activity, etc.[87]  
BH4 is formed enzymatically from GTP and it is a pyrazino[2,3-d]pyrimidine 
compound.[88] The first experimental evidence of BH4 as a role of a cofactor in NOS 
synthesis was found from studies using several fold stimulation of iNOS in cytosols 
of cytokine-activated macrophages.[89, 90] Further work confirmed these findings and 
added BH4 was found to increase the NOS activity by 2 to 30-fold.[91, 92] BH4 was also 
found to be tightly bound in purified enzyme preparations and also, the enzyme 
activity had a positive correlation of the amount of endogeneously bound 
biopterins.[93-96] 
The functional role of hydroxylating cofactor of phenylalanine hydroxylase was 
established in 1963.[88] Research done over the subsequent years showed that BH4 acts 
similarly for tyrosine hydroxylase and tryptophan hydroxylase. BH4 is therefore 
essential for the hydroxylation of all aromatic amino acids and also in the formation 
of the biogenic amines such as adrenaline, noradrenaline, dopamine and serotonin.[97, 
98]
 BH4 activates oxygen for catalysis during aromatic amino acid hydroxylation 
whereby the dioxygen is likely to be inserted at the 4a-position in the pterin group.[99, 
100]
 The 4a-hydroxy-BH4 is then rapidly dehydrated to quinonoid 5, 6-
dihydrobiopterin which is then recycled to the active BH4 cofactor by dihydropteridin 
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reductase (carbinolamine dehydratase). 7-BH4 is formed via rearrangement of the 4a-










































































Scheme 7 Proposed BH4 utilization in monooxygenation enzymes 
 
BH4 is necessary for the expression of NOS activity. BH4 promotes the coupling of 
NADPH oxidation to NO synthesis and inhibits superoxide and hydrogen peroxide 
formation. Giovanelli et al. had found that citrulline formation in rat cerebellar NOS 
was not stoichiometric with BH4.[101] There were more than 15 equivalents of L-Cit 
produced with every equivalent of BH4 consumed. BH4 was not recycled by NOS and 
added BH4 had little or no effect on the initial rate. Giovanelli et al. therefore 
suggested that BH4 has an allosteric modulator role (rather than a hydroxylating 
cofactor in NOS catalysis) or may function to protect NOS by keeping a crucial 
catalytic component in the reduced state. BH4 however, co-purifies with both 
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constitutive[95] and inducible[53, 96] NOS and BH4 recycling can occur, utilizing 
NADPH in the NOS system.[95] The conclusions made by Giovanelli et al. therefore 
require some modification. Significant levels of ‘free’ BH4 or BH2 are not generated 
and it is actually possible that the enzyme-bound BH4 can redox cycle during enzyme 
turnover utilizing NADPH. BH4 has been shown to promote the formation of the 
active dimeric protein from its inactive monomers.[102]  
Hevel and Marletta have proposed a likely redox role for BH4 in NOS catalysis based 
on studies using purified NOS from macrophages and BH4 analogs.[96] They 
highlighted that their studies could be reconciled with the studies done by Giovanelli 
et al. whereby BH2-BH4 recycling occurred on the NOS protein without prior release 
of an oxidized biopterin intermediate and the BH4 recycling were redox active in a 
non-stoichiometric fashion. The monooxygenase-like N-hydroxylation of L-Arg, and 
also the subsequent oxygenation of NOH-L-Arg to NO and L-Cit are both supported 
by BH4. The enzyme-bound heme is suggested to be involved in this reaction because 
the conversion of NOH-L-Arg to NO is blocked by carbon monoxide.[76-78] There was 
no evidence for the formation of 7-substituted pterins in the NOS reaction as they 
were not detected, even in the absence of dehydratase.[26] All these results argued 
against a redox role for BH4 in NOS but there is some evidence which show that this 
is not totally accurate of the entire picture.  
There is an increasing possibility that the cofactor tightly bound to the enzyme may be 
regenerated at the expense of NADPH, where the rate accelerating effects of BH4 
have been shown to be supported by NADPH in a concentration-dependent way.[103] It 
has been found that the homologous redox-stable pterin, 6(R, S)-methyl-5-deaza-
tetrahydropterin suppresses NOS activity whereas the 6(R, S)-methyltetrahydropterin 
stimulates the initial catalytic rate of purified NOS from cytokine-treated 
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macrophages.[96] This study further proves a redox role of BH4 in NOS. [3H]BH4 as a 
radioligand was used to characterize the pteridine binding site of brain NOS.[104] It 
was revealed that the oxidized derivative BH2 had a fairly high affinity for the enzyme 
and this allows comparison of the effects of the tetrahydro and dihydro forms on the 
NO formation.[105] These studies showed that BH2 is able to completely abolish the 
stimulation of the enzyme by the tetrahydro derivative but did not significantly 
increase basal rates of NO synthesis. Therefore a fully reduced biopterin being bound 
to NOS is only observed during NO synthesis. 
Evidences from further studies done by other groups have pointed an alternative in the 
explanation of the redox role of BH4. Bec et al. initially proposed the possibility of 
the involvement of a pterin radical on the basis of rapid-reaction kinetics.[106] This 
study was further supported by structural information which suggested that a pterin 
species could be involved.[85] Rapid freeze-quench Electron Paramagnetic Resonance 
(EPR) confirmed this hypothesis where direct observation of BH3. which is formed by 
the heme domain of iNOS during the heme oxidation with oxygen. Unfortunately, this 
technique is unable to distinguish between the cation form and the neutral radical 
form.[107] 
Based on the ability of the pterin-binding site of their eNOS heme domain to bind L-
Arg via its cationic groups, when the arginine site was occupied by S-ethylisothiourea,  
Raman et al. proposed that both BH4 and BH3
.
 might be in their protonated cationic 
forms.[85] It was hypothesized that the bound BH5+ donates one electron to the heme 
thereby forming BH4
.+
 which is then returned to the reduced state by accepting an 
electron from a flavin in the reductase domain (Scheme 8).[36]  From all the studies 
done, it seemed most likely that BH4 plays a redox role in NOS catlaysis. It must be 
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noted that in addition to this key catalytic role, other effects of BH4 may also play 
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Scheme 8 Structures of biopterin cofactors involved in NO synthesis 
 
1.5 Approaches to NOS Inhibition 
It is known that the active site of NOS is unique in the biological systems and 
therefore it is logical to assume that the safety of a therapeutic agent will be related to 
the degree to which it is specific for its target versus other systems. Stemming from 
this, drug discovery in the field of NOS inhibitors have mainly been focused on the 
mechanism-based enzyme inhibitors which are directed at the active site of NOS.  
These inhibitors provide the most likely basis for achieving a high degree of target 
enzyme specificity and therefore a greater degree of pharmacological specificity and 
utility. However, there are potential difficulties for NOS inhibition via competition at 
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the substrate-binding site. Firstly, the concentration of substrates present in cells are 
relatively high (typically 10 – 100 fold higher than Km) and the inhibitors will need to 
compete with this high concentration of substrates.[108] The inhibitor therefore needs 
to have a high affinity for the enzyme active site in order to show significant activity 
in cells and in vivo at a reasonable dose. Secondly, the active sites are very highly 
structurally conserved in the L-Arg binding region as showed by comparison studies 
between the published X-ray crystal structures for eNOS and iNOS.[108] Nevertheless, 
there are two principal approaches to drug discovery of NOS inhibitors: (i) substrate-
based inhibitors and (ii) non-substrate-based inhibitors. 
 
1.5.1 Substrate-based Inhibitors 






























The first NOS inhibitors to be reported are mono- or di-substituted guanidine 
analogues of L-Arg which bind at the guanidine-binding site and are competitive with 
arginine for the enzyme’s active site. They are usually poor isoform selective 
inhibitors and none of the reported compounds has been found to show any significant 
selectivity for nNOS either in vitro or in vivo. These inhibitors include L-NG-nitro-
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arginine (L-NNA) (01),[109] L-NG-nitro-arginine methyl ester (L-NAME) (02)[110] and 
L-NG-monomethyl-arginine (L-NMMA) (03).[111]  
The nitration of the guanidine functional group of arginine suppressed its basicity and 
facilitated the chemical synthesis of arginine-containing peptides.[112] The 
nitroguanidino functional group is not protonated in aqueous solution (pKa < 1) even 
though the carboxylate and amino functional groups of L-NNA have pKa which is 
similar to that of arginine. Nitration of the arginine side chain greatly reduces the 
solubility at physiological pH since the basicity is being suppressed.[112] At 37oC and 
pH 7, the solubility of L-NNA is only about 3-5mM.  L-NNA and L-NAME are both 
commercially available, inexpensive and widely used as NOS inhibitors. L-NNA is 
particularly effective in inhibiting the constitutive NOS (nNOS and eNOS) where it 
binds noncovalently but tightly to them. The initial binding with L-Arg is competitive 
but as time progresses, the inhibition increases with time. For the iNOS, L-NNA acts 
as a freely reversible inhibitor which is competitive with L-Arg. As L-NNA does not 
show any tight binding to iNOS, it is therefore a less effective inhibitor for iNOS as 
compared to the constitutive NOS in studies lasting more than a few minutes.[113] L-
NNA inhibits nNOS, eNOS, and iNOS with Ki values of 15nM (bovine), 39nM 
(human), and 4.4µM (murine), respectively.[109, 114] 
L-NAME is a prodrug and the methyl ester is hydrolyzed in the body to give the 
active inhibitor L-NNA. Cellular esterases are involved in the transformation of L-
NAME to L-NNA.[110] It should be noted that although L-NAME is more soluble as 
compared to L-NNA, the concentration of L-NNA increases as L-NAME is 
hydrolyzed. L-NAME can be employed in cases where the NOS is highly purified (i.e. 
esterase free) but it is not a strong inhibitor as compared to L-NNA.[115]  
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L-NMMA is also readily available and is relatively inexpensive. It is the first reported 
inhibitor for NOS activity. Although it inhibits all the isoforms of NOS, it is a more 
potent inhibitor of iNOS as compare to eNOS.[116] Therefore it is probably the most 
widely used in the elucidation for potential roles in iNOS-related diseases. It is not 
surprising that effects of L-NMMA in models of shock vary from inhibition of iNOS 
activity to inhibition of eNOS activity masking the beneficial effects of iNOS 
inhibition to marked inhibition of eNOS activity, as L-NMMA is considered a 
moderately selective inhibitor of iNOS activity. The dosage of L-NMMA 
administered as well as the model of shock will therefore give different results.[117] 
Therefore if L-NMMA is administered in high concentrations, and as a non-selective 
NOS inhibitor, it may cause adverse effects due to excessive inhibition of eNOS 
activity.[118] The Ki values for nNOS (rat), eNOS (human), and iNOS (murine) are 
approximately 0.18, 0.4, and 6µM, respectively.[114, 119] 
The NOS amino product, L-Cit (04), is not a useful NOS inhibitor (Ki > 100µM).[119, 
120]
 Contrastingly, L-thiocitrulline (L-TC) (05) is a strong inhibitor and is available 
commercially.[121] L-TC is stable to acid and is soluble in water and physiological 
solutions. The inhibition of NOS by L-TC is reversible and competitive with L-Arg. 
[119]
 The reported Ki values for nNOS (rat cerebellar) and iNOS (vascular smooth 
muscle) were 0.06µM and 3.6µM respectively.[119] It is noted that there is in particular, 
no formation of citrulline from L-TC. The sulfur of L-TC was established to interact 
as a sixth axial ligand with the heme iron of NOS by both optical and EPR 
spectroscopy.[122] L-TC perturbs the heme iron without forming a direct bond in its 
predominant binding mode. 
S-Methyl-L-thiocitrulline (L-SMTC) (06), S-ethyl and S-propyl compounds are found 
to be very potent NOS inhibitors.[121] L-SMTC is available commercially and the 
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initial binding of L-SMTC to NOS is competitive with L-Arg.[121] There is no 
evidence found for irreversible covalent inhibition even though the methylthio group 
of L-SMTC is potentially displaceable by active site nucleophiles. Optical 
spectroscopy studies also did not show any indication that L-SMTC ligates directly 























The importance of the guanidine nitrogen was illustrated by two compounds, N-(1-
iminoethyl)-ornithine (07)[124, 125] and 2-amino-5-(guanidinosulfanyl)pentanoic acid 
(08).[126] 1-(iminoethyl)-ornithine has similar potency as compared L-NMMA. The 
reported IC50 values for rat nNOS and mouse iNOS are 3.9µM and 2.2µM 
respectively.[126] It was interesting to note that a one carbon chain elongation of (07) 
gave an iNOS selective compound (09) with reported IC50 values for rat nNOS and 
mouse iNOS to be 92µM and 3.3µM respectively.[126] These results demonstrated that 
there were actually minor differences between the active sites of nNOS and iNOS. 
The replacement of the chain nitrogen with methylene[27] or sulfur[126] resulted in 
compounds that were inactive. This indicates that the chain nitrogen (NH) is 
important for binding either through binding with an acidic residue or through 
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hydrogen bonding. Similar potencies were achieved with compounds synthesized 
from the replacement of part of the saturated carbon chain with sulfoxides, sulfones or 
unsaturation groups.[127, 128] The acid moiety, when replaced with a diol, resulted in a 
compound (10) with more selectivity but of similar potency.[129, 130] The reported IC50 



























Analogues of the mechanism-base inhibitor N-allyl-L-arginine were prepared in order 
to better understand the arginine binding site.[131, 132] It was found that the ester (13) 
and the parent compound (11) have similar potencies against bovine nNOS. This 
might conclude that the amine moiety is more important for binding as compared to 
the acid function on the assumption that the ester is not hydrolyzed to the acid.[131, 132] 
The acid moiety of L-NNA was substituted with alcohol from studies made by Murad 
et al.[133, 134] One of the analogues of L-NNA with the acid moiety replaced by alcohol 
and also unsaturation in the chain was synthesized (14). The reported IC50 values for 
rat nNOS and mouse iNOS for (14) were 3.0µM and 75µM respectively.[133, 134] 
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Studies on α-phosphinic and phosphonic acid derivatives of L-NNA and L-NMA 







































1.5.1.2 Conformationally Restricted Arginine Analogues 
Conformationally restricted arginine analogues (15-23) were designed in the hope to 
increase the selectivity and also to better understand the preferred orientation of 
binding of amino acid-based inhibitors within the arginine binding site.[136-138]  
Conformationally restricted arginine analogues are compounds in which the free 
rotation of the methylene chain present in L-Arg analogues is hindered by the 
introduction of various rigid scaffolds. They were generally weak inhibitors with 
moderate selectivity when compared to the parent molecules. From the reported 
results, conformational restriction appeared to prevent the molecules from assuming 
the appropriate discriminatory binding orientations needed for high selectivity of the 
isoenzymes of NOS; therefore, the imposition of restricted conformations in the 






















15a, R = NH2
15b, R = NHCH3
15c, R = CH3
16a, R = NH2
16b, R = NHCH3
16c, R = CH3







































21a: 2S, 3S, 5S
21b: 2S, 3S, 5R














LNNA- containing dipeptides is another group of amino acid-based analogues. In 
order to improve the selectivity in favor of nNOS, Silverman et al. designed L-NNA 
(ArgNO2)- and phenylalanine (Phe)-containing dipeptides and dipeptide esters.[139] 
Among the synthesized derivatives, two compounds exhibited an inhibitory 
preference for nNOS over iNOS and eNOS with Ki (nNOS, iNOS and eNOS) values 
determined as 2, 3600 and 5mM for (13) and 17, 13600 and 90mM for (14), 
respectively. (13) could not be therapeutically useful as it is similar to L-NNA which 
does not have much selectivity against the three isoforms. 
Silverman et al. went on to synthesize a library of 152 dipeptide amides containing L- 
and D-NG-nitroarginine (D-NNA) and a variety of amino acids and they were 
screened for activity.[140] A more accurate Ki data measurement was done with ten of 
the most nNOS-selective inhibitors selected. Several analogues were relatively potent 
and selective nNOS inhibitors; L-NNA-L-Dbu-NH2 (15) had a Ki of 130 nM with 
1538-fold selectivity for nNOS over eNOS and 192-fold selectivity over iNOS. D-
NNA-L-Lys-NH2 (16) showed maximal selectivity of 2765-fold for nNOS over iNOS 
and good selectivity of 135-fold for nNOS over eNOS.[140] It was suggested that both 
steric and electronic effect play important roles in the binding of these dipeptide 
inhibitors to the enzyme. The basic amine or imine side chains could interact with the 
active site of nNOS through ionic or hydrogen bondings. The protonated basic 
nitrogen could also interact electrostatically with the nNOS but not with eNOS.[140]  
Although dipeptides, such as (15), produce exceptional biological activity, they are 
not desirable as drug candidates. Peptide-based compounds tend to exhibit poor 
bioavailability as the peptide bond can be hydrolyzed and easily be metabolized in the 






































Peptidomimetic modifications such as incorporation of protecting groups at the N-
terminus of the dipeptide amide (15) or masking the NH- group of the peptide bond 
resulted in a dramatic loss in potency of nNOS.[141] This demonstrated the importance 
of the α-amino group of the dipeptide and NH moiety of the peptide bond for binding 
at the active site. The deletion of the carboxamide group (17 – 19) did not have any 
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The poor bioavailability issue could be solved by using the peptidomimetic approach 
which potentially could increase the bioavailability. The reduced amide bond 
analogues (20 – 22) were therefore synthesized.[142] (20) showed the best potency over 
nNOS with Ki of 120 nM. It also had the highest selectivity over iNOS (320-fold) and 
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eNOS (greater than 2500-fold) in this series of reduced amide bond analogues. The Ki 
values for the nNOS isoform for (21) and (22) were 290 nM and 460 nM 
respectively.[142] By comparing the data for (20 – 22) with (17 – 19), it was apparent 
that the potency on nNOS and iNOS was more or less the same or only slightly 
increased a little. The potency for eNOS on the other hand, has greatly decreased. The 
selectivity for nNOS over eNOS for (20 – 22) implied that the carbonyl moiety of the 
amide bond might not be necessary for its activity towards nNOS and iNOS. The rigid 
–CO-NH- group interacts better with the active site of eNOS as compared to the 
reduced, flexible –CH2-NH- group. The non-basic amide bond when reduced becomes 
the corresponding amine which is basic and may not bind as well to the eNOS. The 
reduced amide bond analogues gave potencies similar to that of nNOS but there were 
great increased in selectivities over eNOS and iNOS.[142] Therefore from these studies, 
potent and selective dipeptide inhibitors for NOS might be developed in the near 
future.  
 
1.5.1.4 Non-amino Acid-based Inhibitors  
Non amino acid-based inhibitors were developed and studied for improvement of the 
selectivity and the therapeutic profile of L-Arg derivatives. They include structures 
like guanidines, isothioureas, amidines and thiazines. They are often bulky and can 
extend into the substrate access channel which is far from the highly conserved 
catalytic centre.  
It has been reported that guanidine has no NOS inhibitory activity but several N-
substituted analogs have been shown to inhibit iNOS activity.[143] The guanidine 
moiety can mimic L-Arg for recognition at that binding site even though simple 
guanidines are considered weak inhibitors.[143] Therefore the guanidine moiety can be 
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considered a potential pharmacophore for inhibition of NOS. Aminoguanidine (23) 
was the first selective inhibitor of iNOS (mouse iNOS either in enzyme, cell and 
organ-based assay) described (IC50 values for nNOS and eNOS: 160µM and 5.4µM 
for iNOS).[144] (23) is not a very potent inhibitor of iNOS activity even though it is 
more potent inhibitor for iNOS activity as compared to eNOS activity. (23) is a 
mechanism-base inhibitor as the inhibition of NOS by (23) will increase with 
increasing incubation time.[145] Other guanidines such as 1-amino-2-hydroxy-
guanidine (24), 1-amino-2-methyl-guanidine (25), 1-amino-1-methyl-guanidine (26) 
and 1-amino-1, 2-dimethyl guanidine (27) also inhibit iNOS activity.[146] (24) has 
been found to be a more potent, more selective and possesses better solubility 

































Isothiourea-containing compounds are potent and selective inhibitors of human iNOS 
and eNOS as seen from SAR and biological studies.[147-149] Isothioureas with short 
alkyl chains on the sulfur atom and no substituents on the nitrogen atoms are the most 
potent of isothioureas. S-Ethylisothiourea (28) is a potent but isoform non-selective 
inhibitor of human NOS with Ki values of 0.019µM, 0.029µM and 0.039µM for iNOS, 
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nNOS and eNOS respectively.[149] The sulfur atom of (28) plays an important rule in 
binding as it binds near the heme of iNOS. The S-ethyl substituent is small enough to 
be able to fit into a small hydrophobic pocket on the iNOS enzyme. S-substituted 
isothioureas inhibit nNOS but they do not cross the blood-brain barrier.[149] The 
binding with L-Arg is competitive and fully reversible for most of these inhibitors.[147-
149]
 S-propargylisothiourea (29) is an exception where it shows NADPH-dependence 
and a mechanism-base inactivation.[150] It must be noted that the isothioureido carbon 
of these S-substituted isothioureas are subjected to nucleophilic attack under some 
conditions and they may react with various biological molecules in complex systems. 
Further studies on this will need to be done in order to address this issue.  
N-phenylisothioureas have been reported as potent and selective inhibitors of human 
nNOS.[151] SAR studies of these compounds have demonstrated that the constitutive 
NOSs are more tolerable as compared to iNOS towards structural modifications, 
which gave rise to inhibitors with greater selectivity for nNOS versus iNOS than for 
eNOS. S-ethyl-N-[4-(trifluoromethyl)phenyl]isothiourea (30) was found to be the 
most interesting compound from a series of N-phenylisothioureas. However, it 
possesses poor cellular penetration. It has the following Ki values of 37 µM, 0.32 µM 
and 9.4µM for iNOS, nNOS and eNOS respectively (Ki ratios iNOS/nNOS and 
eNOS/nNOS were 45 and 29 respectively).[151]   
Bis-isothioureas have also been reported to have selectivity for human NOS.[149] S, S’-
(1,3-phenylenebis(1,2-ethanediyl)bisisothiourea (PBITU) (31) inhibits human NOS 
with Ki values of 0.047µM, 0.25µM and 9µM for iNOS, nNOS and eNOS 
respectively.[149] Another very potent and partially selective nNOS inhibitor (32) was 
reported in the same study. The Ki values were 0.0013µM, 0.0087µM and 0.090µM 
for iNOS, nNOS and eNOS respectively.[149] This type of inhibitor may be binding to 
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both active sites of the dimeric enzyme due to its symmetrical structure. The binding 
mode of one of the isothioureas was proposed to be similar to that of (28) but the 
binding of the rest of the molecule may be the portion imparting the selectivity to the 
molecule. The cellular penetration and systemic toxicity of these isothiourea-based 
























The problem of bisisothiourea toxicity was addressed by Garvey et al. who designed 
amidine analogues of PBITU.[152] 1400W (33), which is a monoamidine monoamine 
analogue, has been found to be a slow, tight binding of human iNOS. 1400W was 
found to inhibit iNOS 5000-fold more effectively than eNOS and 200-fold more 
effectively than nNOS. The inhibition of the activity of human iNOS by 1400W was 
extremely potent (Kd value ≈ 7nM) and was dependent on the NADPH cofactor. The 
mechanism of this inhibition was either irreversible or extremely slow reversible. and 
hence 1400W therefore would be an ideal tool to elucidate the role of NO from iNOS 
in shock and other diseases associated with the induction of iNOS since it appears to 










A group of very potent and selective bisamidines inhibitors was reported by 
Macdonald et al. A weak and non-selective lead (34) was initially synthesized. The 









The amino acid moiety was found to be not essential for inhibition after a comparison 
of the potency and selectivity between amino acid-based and non-amino acid-based 
inhibitors of the human isoforms.[154] Several derivatives of simple amidines were 
tested and they were found to be potent but non-selective. Cyclopropylcarbamidine 
(35) and 2-thienylcarbamidine (36) were found to be the most potent for human iNOS 
with IC50 values of 5.2µM and 6.5µM respectively. (36) and 2-methylthioacetamidine 
(37), on the other hand, were potent compounds for human nNOS with IC50 values of 
2.9µM and 3.9µM respectively. The amidine group by itself could be considered as a 














Cyclic amidines have also been studied in NOS inhibitions. 2-iminopiperidine (38) 
and 2-iminohomopiperidine (39) were potent but non-selective inhibitors of human 
iNOS versus human eNOS.[155] More potent and selective inhibitors of human iNOS 
were achieved with substitution on the ring of (38) and (39). Among the 2-
iminopiperidine derivatives, 4- methyl (40), 6-methyl (41) and 4, 6-dimethyl (42) 
compounds were the most potent inhibitors of human iNOS with IC50 values of 
0.1µM, 0.5µM and 0.08µM respectively.[156] The cyclohexylmethyl was the most 
selective out of this six membered ring series even though it is less potent (IC50 ratio 
eNOS/iNOS = 64).[156] Better results on the selectivity were obtained, particularly 
with 7-propyliminohomopiperidine (43) (introduction of propyl functional group at 
the 7-position of 2-iminohomopiperidine) which has an IC50 value of 160µM against 






















1.5.2 Non-substrate-based Inhibitors 
1.5.2.1 Heme Binding Agents 
These are inhibitors that do not contain any amidine or guanidine functionality and 






















7-Nitroindazole (7-NI) (44) is an isoform non-selective NOS inhibitor and studies 
have shown that it interacted competitively with the substrate binding site on the NOS 
enzyme with L-Arg.[158] This was supported by the study in which (44) displaces the 
binding of L-[3H]NAME to rat brain cytosolic NOS. The binding of (44) is also 
competitive with respect to BH4 and exhibited a Ki of 0.16µM.[159] It has been 
suggested that (44) binds to the heme prosthetic site of the enzyme in such a way that 
it impedes the access of both L-Arg and BH4. Several studies on indazole (45), 5-
nitro- (46), 6-nitro- (47) and (44) show them inhibiting bovine nNOS and eNOS with 
IC50 values of 2.3mM, 1.15mM, 40µM and 1.5µM respectively in the presence of 
0.12µM L-Arg. Inhibition by 7-NI was competitive versus BH4 and non-competitive 
versus L-Arg for mouse iNOS (Ki = 1.6µM). The Ki was found to be lower, 0.8µM, 
for the mouse nNOS and eNOS.  
 











Imidazole (48), 1-phenylimidazole (49), 2-phenylimidazole (50) and 4-
phenylimidazole (51) were reported to inhibit bovine nNOS and eNOS with IC50 
values of 200, 25, 160 and 600µM respectively in the presence of 0.12µM L-arg.[160] 
The cytochrome c reduction (a heme-independent NOS-catalyzed reaction) was not 
inhibited and this reinforced that these compounds bind as heme ligands. (48) 
inhibition is competitive with eNOS but not with nNOS and iNOS and is non-
competitve with BH4 for all the isoforms.[160] (49) exhibits significant selectivity for 
iNOS even though (48) inhibits all isoforms of NOS. (49) shows competitive binding 
with BH4 but not with iNOS, whereas it was shown to be competitive with both BH4 
and arginine against eNOS.[160] 
It has been reported that imidazoles which target anti-fungal acitivities were able to 
inhibit NOS activity. These anti-fungal imidazoles do not only interact with the heme 
at the active site, but also act in competition with CaM. They were also shown to 
either inhibit or promote dimerization, which affect the assembly of iNOS monomers 
into active dimers.[160] 
 
1.5.2.2 BH4 Inhibitors 
All the isoforms of NOS require the cofactor BH4 for catalytic activity. As BH4 is 
known to function as a cofactor for only four other known enzymes (the aromatic 
amino acid hydroxylases), by interfering with BH4 synthesis or utilization, it provides 
a potential means for selectively blocking NO synthesis.[161] 
4-amino substituted pteridines were shown to be potent NOS inhibitors in intact cells 
and downregulate NO formation.[161] A structure-activity relationship (SAR) for 
nNOS was developed by variations of 4-amino pteridine at the 2-, 4-, 5-, 6-, and 7- 
position. There was no significant inhibition of nNOS observed upon substitution of 
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positions 2, 5 and 7.[161, 162] A significantly increase in affinity of reduced 4-amino-
BH4 was observed when bulkier substituent such as phenyl group was substituted at 
position 6 (52 – 53). This was due to favorable hydrophobic interactions to nNOS and 
this observation was not seen in aromatic 4-amino pteridines. The reported IC50 



















Potent nNOS inhibitors (54 – 57) were achieved when two hydrophobic substituents 
at the four position and also 6-arylation of aromatic 2, 4-diamino pteridines was 
synthesized. These inhibitors are similar to inhibitors of dihydrofolate reductase 
(DHFR) but they do not interfere with phenylalanine hydroxylase as member of the 
amino acid hydroxylase (AAH) family.[161, 163] 4-amino BH4 also inhibits 
dihydropteridine and folate reductase. The reported IC50 values for the nNOS isoform 






























The discovery of reduced 4-oxo-pteridines with modifications favorable for nNOS 
inhibition was made with electron-rich aromatic phenyl or benzoyl groups at 5- and 6-
position (58 – 61).[164] Again, hydrophobic and electrostatic interactions with Phe-462 
and Ser104 in the BH4-NOS binding site were responsible for this inhibitory effect. 
This increased in binding affinity for nNOS indicated that the 6-position is important 
in general to the binding to the active site. The reported IC50 values for the nNOS 
isoform for (58 – 61) were 32µM, 25µM, 7µM and 35µM respectively.[164]  
Docking studies showed that the aromatic 4-oxo-pteridine scaffold better tolerates 
additional steric bulk at C6 as compared to the reduced series (62 – 64). The reported 
IC50 values for the nNOS isoform for (62 – 64) were 26µM, 27µM and 33µM 
respectively.[164] The binding affinity of aromatic 4-oxo-pteridines was also found to 
be influenced by substituents in the 2-position as the addition of steric bulk attenuates 
the favorable effect of C6 substitution. The binding modes of 4-oxo and 4-amino 
derivatives bound to eNOS were confirmed by subsequent X-ray structures. These 
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findings suggested that the 4a-amino substituent is not essential in developing pterin-






















































1.5.2.3 Flavoprotein Reductase Inhibitors  
Due to the fact that NOS require NADPH-dependent FAD and FMN, it would be 








Diphenyleneiodonium (DPI) (65) and its analogues which are known to be inhibitors 
of NADPH-flavoproteins were found to be fairly potent inhibitors of both iNOS from 
macrophages and eNOS and nNOS from endothelial cells.[165] The inhibition of NOS 
by these inhibitors was found to be time and temperature dependent, irreversible 
(formation of covalent bonds) and also independent of enzyme turnover. (65), di-2-
thienyliodonium (DTI) (66) and iodoniumdiphenyl (ID) (67) are potent flavoprotein 
inhibitors which are capable of covalent and irreversible enzyme modification. DPI, 
DTI and DI was found to inhibit iNOS with IC50 values of 50, 100 and 150nM 
respectively when they were added to standard assay mixtures.[165] The inhibition of 
iNOS was completed in about 10 min in buffer alone but was delayed to about 30 min 
in reaction mixtures containing NOS substrates and cofactors. NADPH, FAD and 
FMN each afforded significant protection during direct testing of individual reaction 
mixture components. Further studies established that DPI is a potent in vivo and in 
vitro irreversible inhibitor of endothelium-dependent vasorelaxation in rat aortic 
rings.[165] This inhibition was suggested to be due to the antagonism effects of FAD 
and NADPH. The use of DPI may be of limited value because of the ubiquitous 
distribution of NADPH-dependent flavoproteins. Therefore it seems unlikely that 
such compounds will have selectivity or specificity to be useful as approaches for 


















































Both nNOS and eNOS are activated and regulated by Ca2+ through the reversible 
binding of CaM whereas for iNOS, it is not since CaM is found to be tightly bound 
and is more of an enzyme subunit. Therefore CaM antagonists should have a 
significant effect on nNOS and eNOS, but with little or no effect on iNOS. 
Trifluoperazine (68),[166] Chlorpromazine (69),[167] Calmidazolium (70),[168] W-5 
(71),[169] W-7 (72),[168] W-9 (73),[169] W-12 (74),[169] W-13 (75)[169] and 
phenoxybenzamine (76)[170] were found to be CaM antagonists. They not only inhibit 
NOS but also other CaM-dependent enzymes and presently they do not appear to be a 
promising avenue in the discovery of selective inhibitors of NOS. 
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1.6 Synthesis of Nitroguanidines 
In 1887, a compound which was thought to be nitrosoguanidine was described by 
Jousselin.[171] The synthesis of this compound was carried out with guanidine nitrate 
being dissolved in fuming nitric acid and nitrous oxide was bubbled through the 
solution. The solution was then heated for a few minutes and was poured into water to 
induce precipitation of the product. In 1889, Jousselin reported another improved 
method of synthesizing this compound from guanidine nitrate and fuming nitric 
acid.[172] This misconception was finally cleared when this compound was proved to 
be nitroguandine in 1891 by both Pellizzari[173] and Franchimont[174] when they 
repeated the preparation of Jousselin.[172] In 1892, nitroguanidine was generated by 
nitration of guanidine thiocyanate and by treating guanidine nitrate with a mixture of 
fuming sulfuric and nitric acids as reported by Thiele.[175] The yield reported by 
Thiele was 46.5%. When nitrosoguanidine was oxidized in nitric acid with potassium 
permanganate, nitroguanidine was formed as the major product.[176] It was also found 
that when the benzenesulfonate and p-toluene-sulfonate of guanylurea were treated 
with fuming nitric acid, they were converted to nitroguanidine with ≈ 60% yield.  
The above procedures have caused the evolution and extensive studies of the 
preparation of nitroguanidine. Therefore the preparation of nitroguanidine could be 
divided into two methods. They are the nitration of guanidine sulfate[177-180] and 
nitration of guanidine nitrate respectively.[172, 173, 175, 181] The reaction of guanidine 
nitrate with concentrated sulfuric acid is the most important method of synthesizing 
nitroguanidine. There are three methods of preparing nitroguanidine from guanidine 
nitrate which employed the use of (a) concentrated sulfuric acid, (b) nitric acid, and (c) 
a mixture of sulfuric and nitric acids.[182] Ewan et al. reported a yield of 87.1% when 
guanidine nitrate was reacted with 92-98% sulfuric acid for 48 hours at below 30 to 
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40oC.[182] With 87-95% of sulfuric acid used and a reaction time of 30 min, high 
yields of nitroguanidine were also obtained. A detailed study found that pure 
guanidine nitrate was necessary in obtaining high-grade nitroguanidine.[183] A high 
yield of 92% was constistently achieved when the ratio of sulfuric acid to gunanidine 
nitrate was increased (from 1.65:1 to 3:1).[183] 
In 1954, it was reported that nitration of S-alkyl thiopseudourium salts gave stable and 
water-insoluble products. The S-alkyl thiopseudourium salts were formed either by 
reaction of the sulfate salt with fuming nitric acid and concentrated sulfuric acid 
mixture at a low temperature of -10 to 5oC, or by adding nitrate salt to cold 
concentrated sulfuric acid.[184] 
N1-Alkyl-N2-nitroguanidines can be synthesised by several approaches such as 
nitration of N1-alkylguanidines by nitric acid. This nitration reaction however is not 
specific to guanidine. An alternative synthetic approach involves the substitution of 
alkylamines on nitroguanylating agents, such as N-nitroguanidine or SMNNITU. The 
reaction is likely to be complicated by side reaction (N2O being produced) and it is 
also not suitable for the synthesis involving higher secondary amines and therefore 



















Scheme 9 Synthesis of N1-alkyl-N2-nitroguanidine 
 
The synthesis of N1-alkyl-N2-nitroguanidine was conducted through the nucleophilic 
substitution (SN2 reaction) of alkylamine with SMNNITU, which was in turn was 
synthesized from the nitration of S-methylisothiourea sulphate (SMITUSO4) (Scheme 
9). 
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Due to the presence of the electron-withdrawing nitro group, SMNNITU is considered 
less basic as compared to SMITUSO4. SMNNITU is therefore considered more 
electrophilic as compared to SMITUSO4 and readily reacts with a nucleophile such as 
an amine. It is worth to note that the reaction of SMNNITU and amine requires that 
both reagents exist in their free base form as the amine HCl salt was unable to react 
with SMNNITU.[186] 
 
1.7 Synthesis of Guanidino-containing Heterocycles 
There are several synthetic routes to guanidino-containing hetereocycles and the 
following will describe some of the synthetic routes used to synthesize the guanidino-
















































Scheme 10 Synthesis of 3-amino-5-phenyl-1, 2, 4-triazole 
 
The reaction of hydrazide (77) with S-methylisothiourea provided N-
acylaminoguanidine (78) (R= H, 90%; R= Ph, 86%) which was further cyclized on 
heating to reflux in H2O to the corresponding triazole (79) (R= H,  90%; R = Ph, 97%) 





















N2H4, EtOH, rt, 














CHCl3, rt, 1 h




Scheme 11 Synthesis of N3-phenyl-1H-1, 2, 4-triazole-3, 5-diamine 
 
Partial aminolysis of N-cyanodithiocarbonimidate (81) with phenylamine (80) 
followed by cyclization of the N-substituted N’-cyano-S-methylisothiourea (82) with 




































Scheme 12 Synthesis of 2-benzyl-[1, 2, 4]triazolo[1, 5-a][1, 3, 5]triazine-5, 7-diamine 
 
The synthesis of 5-aza-purines such as 85 proceeded with liberation of ammonia and 
required high temperature (reflux in DMF) or acidic catalysis (HCl) in aqueous 
medium. This heterocyclization reaction was found to be regioselective and only 85  































































Scheme 13 Synthesis of 2-amino-4H-1, 3, 5-triazino[2, 1-b]benzoxazol-4-one, 2-
amino-4H-1, 3, 5-Triazino[2, 1-b]benzothiazol-4-one and 2-amino-4H-[1, 3, 
5]triazino[2, 1-b][1, 3]benzoxazole-4-thione 
 
Scheme 13 shows the synthesis of 2-amino-4H-1,3,5-Triazino[2,1-b]benzoxazol-4-
one, 2-amino-4H-1,3,5-triazino[2,1-b]benzothiazol-4-one and 2-amino-4H-
[1,3,5]triazino[2,1-b][1,3]benzoxazole-4-thione using microwave synthesis. 2-amino-
4H-1,3,5-Triazino[2,1-b]benzoxazol-4-one and 2-amino-4H-1,3,5-triazino[2,1-
b]benzothiazol-4-one were reacted with phenyl isocyanate respectively under 
microwave irradiation (180°C, 15 mins). 2-amino-4H-[1,3,5]triazino[2,1-
b][1,3]benzoxazole-4-thione was obtained when phenyl isothiocyanate was used 
instead of phenyl isocyanate under the same conditions. High yields and short 
reaction times for these compounds were achieved via microwave-assisted ring 
closure synthesis.[189] 
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CHAPTER 2: HYPOTHESIS, OBJECTIVES AND EXPERIMENTAL DESIGN 
 
Through molecular probing[192] and X-ray crystallographic studies,[192-196] the 
potential binding sites for inhibitor interaction with NOS bound to L-Arg are shown 
schematically in Figure 4. The active site is believed to be made up of a guanidino-
binding site (GBS), a region adjacent to the guanidino-binding site (RegG), a α-acid 
binding site (NBS), the α-amino binding site (CBS) and a substrate access channel 
binding site (SacBS).  
As shown in Figure 4, the guanidino portion of L-Arg binds to the GBS and with the 
















Figure 4 Potential binding sites for inhibitor interaction showing NOS bound to L-
Arg 
 
The GBS is the catalytic site responsible for generating NO from L-Arg. It can be 
subdivided into distal GBS and proximal GBS. The distal GBS was found to possess 
extensive hydrogen bonding network and a positively charged Glu residue was 
located just adjacent to the distal GBS. Therefore, binding of hydrogen-bond donating 
and polar groups are well suited for the distal GBS but this cavity is small and cannot 
tolerate even methyl substitution on NH2 group.  As for the proximal GBS, it is 
believed to be where the heme group binds to one of the terminal guanidino NH2 of L-
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Arg, and oxidises the NH2 to give NO.  Moderately sized groups, such as propyl and 
allyl, was able to be accommodated in a hydrophobic pocket identified above the 
heme binding cavity of proximal GBS.[197] Some degree of isoform selectivity could 
be achieved due to the varying size and ligand-compatibility of proximal GBS among 
the NOS isoforms.[197]   
There is limited data in the literature which indicates that the interactions involved in 
RegG are hydrophobic[108] in nature but it was suggested to be the major driving force 
for induced-fitting of inhibitors to the NOS active site.[198] 
In the design of NOS inhibitors, the NBS and CBS are extensively exploited. 
Electrostatic interactions and also extensive hydrogen bonding networks are found 
around these binding sites. Stereospecific preference towards L-amino acids is 
observed with both the NBS and the CBS act together.  The binding affinity of an 
inhibitor is greatly enhanced when there is interaction with either one or both of the 
NBS and CBS binding sites. In terms of isoform selectivity, both binding sites 
however, do not allow much differentiation of the isoforms. The SacBS is located in 
the region further away from the heme and several differences in protein residues are 
identified which may provide promise for isoform selectivity.     
Previous study from our laboratory discovered[186] a lead compound, N1-
diphenylmethyl-N2-nitroguanidine (I) that inhibited nNOS selectively over iNOS and 













Figure 5 N1-Diphenylmethyl-N2-nitroguanidine I 
 
Nitroguanidine and its derivatives were extensively studied for their ultraviolet 
absorption spectra and it was indicated that nitroguanidine exists as a resonance 
hybrid of several electronic structures as show in Figure 6 below.[199] It was also 
suggested in theory by Lamberton that no one bond of nitroguanidine is uniquely 

















Figure 6 Resonance hybrid structures of nitroguanidine 
 
Based on how L-Arg interacts with the active sites, an attempt to rationalize the 
interaction between I and the active site of nNOS was made. It was postulated that I, 
with its nitroguanidino group, would interact with the GBS. The diphenyl moiety on 
the other hand, would interact with RegG which would be hydrophobic. It was 
hypothesized that structural modification on one of the phenyl rings would improve 
the binding affinity as it would enhance interaction with either or both the NBS and 
the CBS.  
We were interested to investigate to what extent the NOS enzyme would tolerate the 
diphenyl rings in the RegG. Therefore it was hypothesized that structural modification 
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of one of the two phenyl rings in I would change the inhibitory activity and selectivity 
of the ligand.  
From previous study,[186] nitroguanidino compounds (II) (Figure 7 and Table 1) with 
substituents on the meta-position of the phenyl ring gave improved inhibitory affinity 
as compared to the para substituents (Table 1). Ortho-substituted groups were not 
designed in the previous study as they were found to be positioned too close to the 










Figure 7 General structure for nitroguanidino compounds II 
 
Therefore it was hypothesized that introduction of polar functional groups such as 
alcohol, amino and ester on the meta-position of one of the phenyl rings of I would 
give improved binding affinity as polar functional groups would be able to interact 
with the CBS, the NBS and even the substrate access channel binding site, while 









  nNOS iNOS eNOS 






p-Cl 26 <10 <10 
p-CH3 <10 <10 14 
p-CF3 13 <10 <10 
p-NO2 33 <10 26 
m-Cl 65 <10 37 
m-CH3 47 <10 29 
m-CF3 48 <10 11 
m-NO2 86 <10 34 
 
Table 1 Percent inhibition at 125µM against the 3 isoforms of NOS for compounds II 
 
In a third part of the project, an exploratory study was conducted to investigate if 
compounds such as guanidino-containing heterocycles and polycyclic heterocycles 
would exhibit NOS inhibition. Ten compounds (III to XII) synthesized by Dolzhenko 







































































Figure 8 Guanidino-containing hetereocyclic compounds 
 
Therefore the objectives of this project were: 
1) To synthesize a series of compounds MK-I (Figure 9) with one of the phenyl 
rings (R1) replaced by various ring systems such as pyridine, cyclohydrocarbon, 
naphthalene and thiophene. It is believed that the bulkiness of the diphenyl 
moiety of compound I is responsible for its nNOS selectivity. This set of 
compounds would provide information on how the variation in the ring type 
and size might affect binding, the nNOS selectivity and the extent of inhibition 









Figure 9 General structure for MK-I compounds 
 
2) To synthesize a series of compounds MK-II (Figure 10) with the introduction 
of a side chain with polar functional groups (R1) such as alcohol, amino and 
ester on the meta- position of one of the phenyl rings so as to explore the 
potential interactions with the CBS and NBS and possibly the SacBS. This was 
to investigate if the meta- substituents would improve the binding affinity and 








Figure 10 General structure for MK-II compounds 
 
3) To screen the synthesized compounds for their inhibitory activities against the 
three isoforms of NOS (commercially available enzymes will be used) using the 
radiolabelled L-[3H]-citrulline assay. The percent inhibition and IC50 values of 
the compounds shall be determined and the isoform selectivity shall be deduced. 
4) To screen compounds III to XII for their inhibitory activities against the nNOS 
using the radiolabelled L-[3H]-citrulline assay. 
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CHAPTER 3: RESULTS AND DISCUSSION 
 
3.1 Synthesis of Library MK-I 
It was postulated that the diphenyl moiety of lead compound I[186] would interact with 
the RegG and therefore it was hypothesized that structural modification on one of the 
phenyl rings of lead compound I would impact the binding affinity as it would affect 
interaction with the NBS and CBS. It would be interesting to know how a change in 
one of the phenyl rings to another ring system would improve the selectivity and 
binding affinity of compound I. A proposed retro-synthesis of the target compounds 




















Figure 11 Proposed retro-synthesis 1 of compounds MK-I 
 
Retro-synthesis of MK-I was used to design a suitable synthetic scheme where 
various ring systems would be introduced on R1. MK-I could be dissected into two 
fragments, the amino fragment and the S-methyl-N-nitroisothiourea (SMNNITU) 
fragment. Coupling of the amine with SMNNITU would generate the target 
nitroguanidino compound. A literature search of the different asymmetrical-rings 
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amines showed that they were not available commercially (unlike simple and 
symmetrical amines). A functional group inter-conversion of the amine gave the 
oxime which could be derived from a phenone. Therefore various phenones were 



























Table 2 Different ring systems for R1 of Library MK-I 
 
Based on the retrosynthesis, library MK-I, with one of the phenyl rings of lead 
compound I, substituted with pyridines, cyclo-hydrocarbons, naphthalene and 





















1) neat, 85oC, 30mins 
2) EtOH, rt, overnight
1-01 to 1-09
1-10 to 1-18





Scheme 14 General synthetic scheme for synthesis of Library MK-I 
 
A literature search was performed and it was found that the phenone could be 
converted to the oxime by reacting the phenone with NH2OH.HCl in basic 
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condition.[201] The reaction conditions for the synthesis of intermediates 1-01 to 1-09 
were optimized with refluxing for 1 hour as shown in Scheme 14.  The yields 
obtained for intermediates 1-01 to 1-09 were in the range of 88 to 100%. Reduction of 
the oxime using sodium ethoxide in ethanol (EtOH) did not proceed as reported by 
Schlegel et al.[201] Therefore, another route to reduce the oxime was sought. There are 
different ways to reduce an oxime but they have limitations based on the 
chemoselectivity and economic considerations. It was found that the reduction of 
oximes to amines could proceed via reacting with low cost zinc dust and ammonium 
formate with very high yields.[202] Intermediates 1-10 to 1-18 were therefore 
synthesized according to the procedures stated by Abiraj et al.[202] The reaction 
condition was optimized as described in Scheme 14 and was found to give yields 
from 71 to 99%. The amines were then directly used in the coupling reaction with 
SMNNITU to form the final nitroguandino compounds as reported by Bong,[186] but 
the reaction conditions had to be optimized as showed in Scheme 14. The yields of 
MK-I-1 to MK-I-9 obtained ranged from 48 to 75%. The starting material, 3-
benzoylpyridine, gave the best combined yield of 69% whereas cyclobutyl phenyl 
ketone was found to give the least combined yield of 29% (Table 3).  
The synthesis of the oxime intermediates was relatively straight forward. The oximes 
were obtained in syn- and anti- isomers as shown from thin layer chromatography 
(TLC) and 1H nuclear magnetic resonance (NMR) analyses. Efforts were not taken to 
separate the isomers for each oxime mixtures because in the following step, the 
reduction of the oxime to amine, would result in a racemic mixture of the amine, 
regardless of reducing the syn- or the anti- isomer (Figure 12). The 1H NMR data 
reported were of the syn- and anti- isomers mixture and there was no observable trend 
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in the ratio for the respective intermediates. Figure 12 shows the possible reaction 






























Syn-isomer (R1 > phenyl)
Anti-isomer (R1 < phenyl)
 
 
Figure 12 Possible reaction mechanism of syn and anti-oximes formation 
 
For the reduction of the oxime to the amine, extra precaution was taken to prevent the 
product from precipitating out of the reaction solvent (as it was not very soluble in 
methanol (MeOH)) as any precipitate formed would be filtered away, together with 
the excess zinc powder, and separation was difficult. Therefore control of the reaction 
time was crucial and the reaction had to be monitored closely by TLC for completion. 
The filtrate, which contained the product, was concentrated via rotary evaporator for 
subsequent acid-base workup. Acid-base workups of the residues were found to yield 
pure amines (71 to 99%), as confirmed by 1H NMR and 13C NMR spectrum.  
The crude racemic amines were then used directly in the coupling reaction with 
SMNNITU to form the final nitroguandino compounds (Figure 13). Several problems 
were encountered during the coupling reaction. The reaction was initially performed 
by dissolving the amine in ethanol and then SMNNITU was added to the stirred 
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mixture[186]. The reaction mixture was subsequently heated to reflux and monitored 
via TLC. Several spots were observed and no main product spot was observed.   
The reaction solvent was then switched to N, N- dimethylformamide (DMF), which 
being polar aprotic, would favor the SN2 coupling of the amine with SMNNITU 
(Figure 13). In this reaction, the amine served as the nucleophile and the SMNNITU 
was the electrophile. The reaction was then allowed to reflux but several spots were 
still observed via TLC analysis. It was suspected that the amine was not stable under 
the harsh reflux condition. Microwave reactions were also attempted with EtOH and 

























Figure 13 Proposed mechanism of coupling reaction with S-methyl-N-
nitroisothiourea to form the final nitroguanidino compounds 
 
The reaction was then repeated under neat condition as the amines were liquids.  
SMNNITU was added to the amine with stirring and heated at 85oC. Bubbles were 
observed as the reaction progressed until the reaction mixture could no longer be 
stirred (foamy solid formed). Based on TLC analysis, the starting material amine was 
still observed and therefore ethanol was added to allow the reaction to be stirred 
overnight at room temperature. A much cleaner reaction was observed with less side 
products formed as compared to all other reaction conditions. N1-α-substituted N1-
benzyl-N2-nitroguanidines were then obtained after purification via column 
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chromatography (DCM:MeOH). Alternatively, recrystallization using EtOH or ethyl 
acetate (EA) could be carried out to afford the pure products. 
Library MK-I compounds were found to be very hygroscopic and handling them 
posed to be difficult. Upon standing on air, the compounds were found to turn from 
solid into sticky viscous liquids. The compounds were therefore dried and stored 
under nitrogen gas. It was thought that formation of the nitroguanidine salts would 
render them more stable for handling but it proved not to be so. Nitroguanidine is a 
very weak base that forms salts only with strong acids. It was reported that these 
nitroguanidine salts were unstable.[203] 
Library MK-I compounds (Figure 14) were characterized by 1H and 13C NMR and 
infra-red (IR) spectroscopies and mass analysis done using electron spray ionization 
spectroscopy (ESI). ESI analysis of MK-I compounds showed a very interesting 
observation. When the temperature of the ESI was set at 250oC, molecular ion peaks 
of the compounds were not observed. The temperature was therefore reduced to 
200oC and still no molecular ion peaks were observed. The temperatures were further 
lowered and finally the molecular ion peaks were observed at a temperature of 100oC. 
From these observations, it could be suggested that MK-I compounds were heat-
sensitive and too high a temperature would cause a decomposition of the compounds.  
Library MK-I compounds were synthesized over a three-step reaction with 
reasonably good yields in every step of the synthesis (Table 3). This reaction scheme 
allowed the synthesis of a small library of N1-α-substituted N1-benzyl-N2-
































































































































































































































Table 3 Yields of intermediates and final compounds for Library MK-I 
a) Isolated yield based on mixture of syn- and anti- isomers. 
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b) Crude yield from acid-base workup show 100% purity from 1H NMR analysis, 
racemic mixture. 
 
3.2 Synthesis of MK-II Compounds 
From previous study,[186] improved binding affinity of nitroguanidino compounds 
with substituents on the meta-position for one phenyl ring was observed. It was 
hypothesized that with the introduction of polar functional groups such as hydroxyl, 
amino and ester on the meta-position of one of the phenyl rings of lead compound I, 
improved binding affinity would be achieved as polar functional groups would be able 
to interact with the CBS, the NBS and even the substrate access channel binding site, 
while retaining the selectivity for nNOS isoform.  
A proposed retro-synthesis of MK-II compounds is shown in Figure 15. As seen 
earlier for library MK-I, MK-II compounds could also be dissected into two 
fragments: the amino fragment and SMNNITU fragment. As amines with substituent 
group on the meta-position of the phenyl ring were not commercially available, 
therefore they had to be synthesized. The amine could be further derived from the 
reaction between benzaldehyde O-methyl oxime fragment and a phenyl lithium 
fragment. The benzaldehyde O-methyl oxime fragment could be synthesized from the 


























Figure 15 Proposed retro-synthesis 1 for MK-II compounds 
 
It was reported that the coupling of the benzaldehyde O-methyl oxime with phenyl 
lithium proceeded via a nitrile intermediate.[204] Therefore in the synthesis of MK-II 
compounds, m-tolunitrile was used as the starting material for direct coupling with 
phenyl lithium instead of with benzaldehyde O-methyl oxime, thereby eliminating 
one reaction step in the reaction scheme (Scheme 15). From Scheme 15, the first 
reaction step proceeded via phenyl lithium coupling. The phenyl lithium reagent was 
prepared accordingly to Schlosser[205] with the temperature kept at -78oC with 
acetone-dry ice bath. The phenyl lithium was freshly prepared by reacting lithium 
wire with bromobenzene under -78oC and anhydrous conditions. m-Tolunitrile was 
then added dropwise slowly to the phenyl lithium reaction mixture to form the imine 
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intermediate. Extra precaution had to be taken to ensure that the temperature of the 
reaction is kept at -78oC as the coupling reaction is very exothermic. An in situ 
reduction of the imine intermediate, formed from the coupling of m-tolunitrile with 
phenyl lithium, to the primary amine was achieved by the addition of borane in  
tetrahydrfuran (THF) to the reaction mixture at 0oC.[204] The t-butoxycarbonylation 
protection (Boc-protection) of the amine was carried out in DCM at room 
temperature.[206] The bromination of the N-Boc-phenyl(m-tolyl)methanamine was 
done by initiation with a 100W lamp (instead of using benzoyl peroxide as initiator) 





















Scheme 15 Synthetic scheme A for synthesis of MK-II diphenyl methylamines 
 
The synthesis of 2-01 proceeded over a two-step in situ reaction. Purification of the 
crude compound via flash column chromatography (DCM/MeOH/TEA = 10:1:0.1, Rf 
= 0.30) gave phenyl(m-tolyl)methanamine (2-01) with a yield of 30%. 
The t-butoxycarbonylation-protection (Boc-protection) of the amino group (2-02) 
proceeded with a good yield of 89%. The subsequent step was the bromination of the 
methyl group on one of the phenyl rings with the reagent, N-bromosuccinimide.[207] 
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Unfortunately, the bromination was found to occur at the benzylic position between 
the two rings system (bis-benzylic position) (2-03) instead of the meta-benzylic 
methyl group on one of the rings as shown from the 1H NMR spectrum. This was 
because the benzylic radical at the two rings system was resonance stabilized and was 
easily halogenated radically by the N-bromosuccinimide reaction as compared to the 
meta-benzylic methyl group. Therefore the initial proposed synthetic route could not 
be carried out further.  
The synthetic route was then modified to introduce the bromine group on one of the 
rings prior to the coupling of the two phenyl rings to alleviate the problem of 












1) hexamine, CHCl3, reflux
2) 50% aq. acetic acid, reflux
(Sommelet reaction)
TiCl3 / NH3





1) PhLi, diethyl ether, -78oC
























Scheme 16 Synthetic scheme B for synthesis of MK-II diphenyl methylamines 
 
From Scheme 16, the starting reagent used was also m-tolunitrile. In this synthetic 
scheme, bromination of m-tolunitrile was done prior to coupling of the two phenyl 
rings. The reaction condition for the bromination of m-tolunitrile was exactly the 
same as reported in Scheme 15.[207]   
m-Cyanobenzyl bromide (3-01) could be converted into an aldehyde via the 
Sommelet reaction.[208] The Sommelet reaction is the process whereby aldehydes are 
produced from arylmethyl halides by the action of hexamine 
(hexamethylenetetramine). There are three stages in the Sommelet reaction: (1) 
formation of a hexaminium salt; (2) hydrolysis of this salt to an amine and its 
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methylene derivative; and (3) formation of the aldehyde. The Sommelet reaction is 
best suited for the preparation of aromatic aldehydes.[208] The proposed reaction 
mechanism of the Sommelet reaction is shown in Figure 16.[209] The hydride transfer 
and the ring-opening of hexamine could also occur in a synchronized manner as 
























































































Figure 17 Proposed concerted hydride transfer and ring-opening of 
hexamethylenetetramine[209] 
 
As reported by Clerici et al., the reduction of m-cyanobenzaldehyde (3-02) to the 
respective benzyl alcohol (3-03) could be achieved by an aqueous system of 
TiCl3/NH3 system without affecting the nitrile functional group.[210] 3-02 was 
dissolved in methanol (MeOH) and ~25% ammonia solution. The aqueous TiCl3 
solution was added dropwise to the solution at 0oC under anhydrous condition. The 
mixture was allowed to warm to room temperature and workup and purification was 
done to afford m-cyanobenzyl alcohol (3-03). The alcohol functional group of 3-03 
was then protected by dihydropyran with p-Toluenesulfonic acid monohydrate (TsOH) 
as the catalyst in DCM and at 0oC to afford 3-04.[211] The coupling of 3-04 with 
phenyl lithium proceeded according to that in Scheme 15.[204, 205] α-phenyl(m-
aminomethyl) benzyl alcohol (3-05) was then reacted with di-tert-butyl dicarbonate in 
DCM at room temperature to form the N-Boc-α-Phenyl(m-aminomethyl) benzyl 
alcohol (3-06).[206] The alcohol functional group of 3-06 was then converted to the 
chloride functional group (3-07) by reaction with thionyl chloride (SOCl2) in CCl4 at 
0oC to room temperature.[212] 3-07 was subsequently transformed to 3-08 by reacting 
with sodium cyanide in EtOH at room temperature, and was allowed to go to 
reflux.[213]   
The bromination of m-tolunitrile to 3-01 was obtained with an 88% yield. The 
conversion of 3-01 to 3-02 was achieved by the Sommelet reaction.[208] 3-03 was 
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found to be sensitive to light and air and handling of this compound possessed 
difficulty. The OH protection of 3-03 with dihydropyran gave a low yield of 49% 
after optimization of the reaction conditions. This low yield could be attributed to 
some side products (not isolated) formed during the reaction as observed from TLC 
analysis. 3-05 was synthesized by the coupling of 3-04 with phenyl lithium with an 
overall yield of 42% over a two-step in situ reaction. The Boc-protection of 3-05 
proceeded with a good yield of 91%. The synthesis of N-Boc-α-Phenyl(m-
aminomethyl) benzyl chloride (3-07) gave a satisfactory yield of 71% whereas the 
synthesis of N-Boc-α-Phenyl(m-aminomethyl) benzyl nitrile (3-08) gave a good yield 
of 90%. There was the disadvantage of protection and deprotection steps in the 
reaction scheme. A protection step and a deprotection step would increase the number 
of steps of the reactions by two. Therefore an attempt was made to optimize the 




















Figure 18 Proposed alternative retro-synthesis 2 for MK-II diphenyl methylamines 
 
Figure 18 shows the proposed alternative retro-synthetic route 2 for MK-II diphenyl 
methylamines. Comparing retro-synthesis 1 (Figure 18) with alternate retro-synthesis 
2 (Figure 15), the first retro-synthesis consisted of a benzaldehyde and an oxmine 
synthons, with benzaldehyde O-methyl oxime as the intermediate. As for retro-
synthesis 2, the selected synthon was a biphenone instead, with the intermediate being 
an un-substituted diphenyloxime.  
Starting from m-tolunitrile, the coupling with phenyl lithium would give the 
biphenone compound after the treatment with acid.[204] It was therefore proposed that 
the formation of the oxime prior to bromination at the meta-methyl position would 
prevent bromination at bis-benzylic position (Scheme 17). As reported by Bandgar et 
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al., the deoximation of oximes to their respective ketones by reagents such as N-
bromosuccinimide was observed.[214] Therefore this synthetic route was not chosen 








1) PhLi, diethyl ether, -78oC







Scheme 17  Proposed synthetic scheme C for synthesis of MK-II diphenyl 
methylamines 
 
 The synthetic route was then redesigned and 3-benzoylbenzoic acid was used as the 
starting material (Scheme 18) since it already possessed the 2 phenyl rings as in lead 
compound I and it is commercially available. The acid functional group at the meta- 
position enabled it for further functional group interconversions into other functional 







































Scheme 18 Synthetic scheme D for synthesis of MK-II diphenyl methylamines 
 
From Scheme 18, 3-benzoylbenzoic acid was converted to the oxime according to 
that reported in Scheme 14.[201] The major difference between the oxime formed in 
Scheme 18 and Scheme 14 was that 3-benzoyl benzoic acid oxime (4-01) contained 
an acidic functional group. 3-benzoylbenzoic acid was therefore converted to 4-01 
without affecting the acidic functional group. This was achieved by first reacting 3-
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benzoylbenzoic acid with hydroxylamine hydrochloride (NH2OH.HCl). Sodium 
hydroxide (NaOH) was used to liberate the hydroxylamine hydrochloride and this 
caused the acidic functional group of 3-benzoylbenzoic acid to be ionized. An acidic 
workup of the crude mixture would then free the acid and leave the oxime functional 
group unaffected.  
α-Phenyl(m-aminomethyl)benzoic acid hydrochloride (4-02) was also synthesized 
according to the procedures stated by Abiraj et al.[202] During the reduction of the 4-
01 to 4-02, extra precaution was taken to prevent the product from precipitating out 
from the reaction solvent (as it was not very soluble in MeOH) as any precipitate 
formed would be filtered away, together with the excess zinc powder, and separation 
of them would posed to be difficult. Close monitoring of the reaction progress was 
therefore essential. The filtrate, which contained the product, was concentrated via the 
rotary evaporator for subsequent acid workup. Acid workup of the residue was found 
to yield pure 4-02, as confirmed by 1H NMR and 13C spectroscopic analyses.  
By the formation of NH2.HCl salts, the problem of coexistence of both acidic (-
COOH) and basic (-NH2) groups was solved. The need for protection and 
deprotection of the amino group could also be avoided, which eliminated additional 
steps in the synthetic route. The reduction of 4-02 to α-phenyl(m-aminomethyl)benzyl 
alcohol (4-03) proceeded through the reduction with BH3.THF.[215] Borane is the most 
commonly used reagent for the reduction of carboxylic acids in the presence of other 
functional groups.[216] α-Phenyl(m-aminomethyl) benzyl chloride hydrochloride (4-04) 
was synthesized accordingly to that reported by Doucet-Personeni et al..[217] 4-04 was 
easily isolated as it precipitated out from the reaction solution and could be easily 
filtered off and washed with chloroform (CHCl3) to afford the pure compound. 4-05 
was coverted to α-phenyl(m-aminomethyl) benzyl nitrile (4-06) by reacting with 
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sodium cyanide in DMF with stirring at room temperature overnight.[213] 4-05 was 
elongated by one carbon by the acid hydrolysis to α-phenyl(m-aminomethyl)acetic 
acid hydrochloride (4-06). 
4-01 was obtained with a very high yield of 99% and it was obtained in syn- and anti- 
isomers as shown from TLC and 1H NMR analyses. Efforts were not taken to separate 
the isomers for each oxime mixtures as the reduction of the oxime to amine in the 
following step would result in a racemic mixture of the amine eventually (Scheme 18). 
The 1H NMR data reported were of the syn- and anti- isomers mixture. The reduction 
of the acidic functional group of 4-02 by BH3.THF gave a reasonable yield of 80% for 
4-03, after purification via flash column chromatography (DCM/MeOH/TEA = 
10:1:0.5%, Rf = 0.35).  
The reaction of 4-03 with thionyl chloride in CHCl3 gave 4-04 with a yield of 84%. 
The reaction of 4-04 to 4-05 however, gave a relatively low yield of 57%. The 
reaction was initially performed under reflux condition in DMF but a lot of side 
products were formed (as observed from TLC analysis) and the desired product 
formed was very little (<10%). Reaction in EtOH and room temperature also did not 
give satisfactory yields. The reaction was performed again and allowed to stir in DMF 
at room temperature overnight and this gave the optimized yield of 57%. Comparing 
this reaction with that of the synthesis of 3-08 (Scheme 3), it was suggested that the 
free amino functional group in 4-04 might have been responsible for the low yield 
obtained. Therefore steps could be taken to protect the amino functional group prior to 
the cyanation reaction in order to obtain the higher yields. 4-05 was then acid 
hydrolyzed to 4-06 with a carbon chain elongated. The yield obtained for 4-05 was 
100%.  
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4-02 was then converted to α-phenyl(m-aminomethyl) benzoate hydrochloride (4-07) 
with a yield of 97%) in order to couple to SMNNITU. It was found that the reaction 
of 4-02 with SMNNITU produced a lot of side products as observed from the TLC 
analysis. This was because in order for the coupling to take place, the amine.HCl salt 
had to be freed and the addition of a base, triethylamine (TEA) was necessary. The 
addition of TEA would render the acidic functional group to be ionized and this 
would also be able to act as a nucleophile in the coupling reaction with SMNNITU. It 
was inevitable that a lot of steps for functional group interconversions of the 
respective functional groups of the intermediates had to be carried out in order to 
elongate the carbon chain. Nevertheless, from this synthetic route, the following two 
nitroguanidino compounds were synthesized, purified and characterized with yields of 















3.3 L-[3H]-citrulline Assays 
There are several assays (such as hemoglobin assay, citrulline assay, nitrite/nitrate 
assay) that are used to monitor the enzymatic reaction of the conversion of L-Arg to 
L- Cit.[218] The assay used in this research work was the L-[3H]-citrulline assay. 
The L-[3H]-citrulline assay a sensitive, specific and discontinuous assay for NOS by 
monitoring the conversion of [3H]arginine to [3H]citrulline as this conversion is 
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stoichiometric with respect to the enzymatic formation of NO.[218, 219] This assay 
employs the use of a small cation-exchange column (Dowex resin) to separate 
[3H]citrulline from [3H]arginine. [3H]arginine, being charged at pH 5.5, will be 
retained by the cation-exchange column whereas [3H]citrulline, which is uncharged at 
pH 5.5, will be separated and collected in the flow through of the cation-exchange 
column. The flow through of L-cit which reflects the amount of NO produced can 
then be quantified via scintillation counting. More than 95% of the [3H]citrulline is 
recovered after chromatography.[218, 219]  
This assay has several advantages over other assays and has become the standard 
assay for NOS activity in crude and purified enzyme preparations. Firstly, the 
technique is sensitive up to the picomolar range due to the use of radioactivity. 
Secondly, the assay is likely to be specific for the NOS pathway as the direct 
enzymatic conversion of arginine to citrulline in eukaryotic cells is unprecedented. 
Thirdly, the separation of neutral citrulline (at pH 5.5) from arginine allows a large 
number of samples (hundreds of enzyme assays) to be processed in a relatively short 
time frame.  
Even though this assay is simple, there are some potential problems to be aware of. 
The pH and changes in the salt concentration can affect the separation step in the 
assay. If the reaction conditions are to be changed, the recovery of citrulline and the 
amount of arginine that does not bind to the resin should always be reassessed. It is 
therefore essential to verify that the Dowex resin effectively retains the charged 
arginine substrate before the start of the assay. Otherwise, a high background value 
would arise which will greatly reduce the sensitivity of the assay. A relatively low 
background value is achieved when more than 99% of the applied radioactivity is 
retained by the column. It is important to purify the arginine prior to the start of the 
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assay if more than 1% of the counts flow through the column. This assay can only be 
used quantitatively if there is no presence of arginine in the NOS. The linearity of 
formation of citrulline over the incubation period must be demonstrated as this assay 
is a discontinuous one.[218, 219] The unit for the radioactivity is counts per minute 
(cpm).  
 
3.3.1 Screening of Library MK-I and MK-II Compounds 
 
The protocol used in this study was adapted with reference to Current Protocols in 
Pharmacology.[220] The NOS enzymes were divided into suitable aliquots for each 
assay. Prior to the start of each assay using the respective NOS enzymes, an 
experiment with a set of different dilutions was performed in order to obtain an initial 
concentration-response curve. This was to determine the range of activity in the 
respective enzyme extracts from the supplier as the activity would vary from batch to 
batch produced. A maximal signal in the linear range would correspond to that of the 
optimal dose of the enzyme extract.  
Optimization of the incubation periods for each of the enzyme isoforms were done to 
produce a linear time-activity relationship so as to ensure the consistency and 
extrapolatability of the data obtained. From the optimization studies, the incubations 
of nNOS and eNOS were carried out at 37oC, with incubation times determined to be 
15 and 20 minutes for nNOS and eNOS respectively. As for iNOS, it was carried out 
at 30oC with incubation time determined to be 20 minutes. Triplicates were done for 
each set of assays and L-NNA (10mM) was used as positive controls in all the assays. 
The compounds were screened and reported based on the percentage inhibition 
against the respective NOS isoforms. 
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The percentage inhibition was derived from the percentage activity where: 
(%)100(%) ActivityInhibition −=  
 
Where:  
positive control = 10mM L-NNA 
negative control = 4% DMSO/H2O 
sample = compound tested 
cpm = counts per minute 
 
Library MK-I and MK-II compounds were prepared to a stock concentration of 
100mM and were further diluted down to 100µM with 4% dimethylsulfoxide (DMSO) 
in a series of enzymatic assays with the respective NOS isoforms.  
Table 4 below shows the percent inhibition at 100µM for libray MK-I and 
compounds MK-II against the three isoforms of NOS with reference to L-NNA 















MK-I-01 11 0.15 14 4.36 < 10 0.17 
MK-I-02 < 10 0.36 < 10 1.53 < 10 0.50 
MK-I-03 36 4.00 45 2.65 < 10 0.61 
MK-I-04 < 10 0.66 < 10 0.58 < 10 0.50 
MK-I-05 31 2.65 30 3.61 < 10 0.35 
MK-I-06 39 2.65 < 10 0.68 20 5.29 
MK-I-07 29 3.61 < 10 0.59 < 10 0.30 
MK-I-08 83 7.94 < 10 1.06 < 10 0.32 
MK-I-09 120 4.58 < 10 0.46 < 10 0.20 
MK-II-01 34 5.23 < 10 0.25 < 10 0.25 
MK-II-02 < 10 0.25 < 10 0.15 16 1.73 
 
Table 4 Percent inhibition at 100µM for library MK-I and MK-II compounds for the 
three isoforms of NOS (Results collated from triplicate experiments) 
 
It had been discussed previously that RegG, which is located in immediate vicinity of 
GBS, could be important in the binding of the inhibitors due to its strategic 
location.[186] The RegG acts as an important bridging region between the GBS and 
NBS/CBS and also the SacBS. Any compound has to interact with RegG in order for 
it to bind to the active site. Based on literature reviews, it was found that RegG is 
often neglected as it was not regarded as one of the key binding sites of NOS. 
Hydrophobic portions of inhibitors (alkyl and phenyl groups) are often found in this 
region. It was thought that only hydrophobic interaction, which is a much weaker 
interaction as compared to ionic and hydrogen interactions, would be involved in the 
RegG.    
From Table 4, some interesting observations could be seen. Comparing MK-I-01, 
MK-I-02 and MK-I-03, which consisted of pyridinyl- rings, it could be seen that 
MK-I-03 gave an inhibition of 36% for nNOS isoform which was better as compared 
to the two other isomers. This suggested that the N in the pyridinyl- ring at the para- 
position was oriented to interact with the active site, therefore giving a higher 
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inhibition as compared to the meta- and ortho- positions. MK-I-03 was found to give 
a higher inhibition of 45% for the iNOS isoform. 
Comparing MK-I-04, MK-I-05 and MK-I-06, it could be observed that as the cyclo-
hydrocarbon ring size increased (from cyclopropane- to cyclopentane), the inhibition 
for nNOS isoform would also increase. The percent inhibition for nNOS isoform was 
found to decrease to 29% when R1 was cyclohexane (MK-I-07).  This observation 
suggested that the active site was only able to accommodate up to cyclopentane ring 
for maximal inhibition for the cyclo-hydrocarbon series of compounds. 
MK-I-08 and MK-I-09 had the inhibition of 83 to 120% against the nNOS isoform 
with respect to the L-NNA positive control.   MK-I-08 and MK-I-09 gave less than 
10% inhibition against the iNOS and eNOS isoforms. Both compounds showed a 
tendency of nNOS selectivity over iNOS and eNOS. MK-I-08 had a naphthalene 
group whereas MK-I-09 has a thiophene group in place of one of the phenyl rings of 
lead compound I. For MK-I-08, the naphthalene ring may be responsible for 
hydrophobic interaction at the active site, thereby giving rise to a high inhibition of 
83%. For MK-I-09, the thiophene ring may be able to fit into the active site pocket 
causing a strong inhibiton of 120% with respect to the positive control (100%), L-
NNA. Both MK-I-08 and MK-I-09 gave less than 10% inhibition for iNOS and 
eNOS isoforms respectively. MK-II-01 was nNOS selective with a 34% inhibition 
whereas MK-II-02 is eNOS selective with a weak inhibition of 16%. 
From these results, it could be seen that both MK-I-08 and MK-I-09 were nNOS 
selective. Futher screenings of the respective compounds could be done (i.e. 
respective IC50), for more conclusive comparison between the results as only one 
concentration (100µM) was screened for all the compounds. 
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3.3.2 Screening of Guanidino-containing Hetereocycles 
In order to explore whether they exhibit any NOS inhibition, ten compounds (Figure 
7) which were synthesized by Dolzhenko et al. [187-191] were screened against the 
nNOS isoform. For a preliminary study on these compounds, we were only interested 
to know if there were any possible inhibitory actions of these heterocycles against the 
nNOS isoform. Hence, the iNOS and eNOS isoforms were not screened in this 
instance. 
The compounds were categorized into monocyclic (III, IV, V), bicyclic (VI, VII) and 
tricyclic (VIII, IX, X, XI, XII) guanidino-containing heterocycles. Only compounds 
III, IV, V, X and XII were soluble in DMSO (100mM) and could be further diluted 
down to 100µM with 4% DMSO/H2O for the biological assays. Compounds VI, VII, 
VIII, IX and XI were not soluble in DMSO which could be due to their bulky and 
hydrophobic structures. From Table 5, it could be seen that compound III gave an 
inhibition of 15% against the nNOS isoform. When a phenyl group was substituted at 
the 5th position of the 1, 2, 4-triazole ring (III), the inhibition increased to 31% (IV). 
The inhibition was decreased to 24% when a phenyl-substituted amine was at the 5th 
position of the 1, 2, 4-triazole ring (V). Compound XII gave an inhibition of 22%.  
Compound X gave the highest inhibition of 44% among the guanidino-containing 
hetereocycles screened at 100µM. This could be due to stronger interactions (e.g. 
hydrogen bonding) of the sulphur with the active site. Compounds 55, 58 to 61 are 
BH4 inhibitors which are non-substrate-based inhibitors. Comparing XII with 55,[161, 
163]
 both compounds contained the guanidino and the piperidyl moieties in their 
structures. Also, comparing X with 58 to 61,[161, 163] which have the 4-oxo-peteridines 
scaffold with the oxygen at the 4th position, X has a carbonyl functional group at the 4 
position and an amino functional group at the 2 position which is similar to that of the 
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4-oxo-peteridines scaffold. It could be seen that compounds X and XII were very 
similar in structures to these BH4 inhibitors and this suggested the possibility of non-
substrate-based inhibition of X and XII. These guanidino-containing heterocycles, 
when compared to MK-I and MK-II compounds, were found to have lower 
inhibitions for the nNOS isoform and the reason could probably be due to them 
inhibiting at the non-substrate sites. 
Also, further screenings of the respective compounds could be done (i.e. respective 
IC50), for more conclusive comparison between the results as only one concentration 
(100 µM) was screened for all the compounds. 
 
 nNOS % Inh ±SD 
III 15 2.65 
IV 31 3.06 
V 24 3.46 
X 44 1.53 
XII 22 3.61 
 
Table 5 Percent inhibition at 100µM for guanidino-containing hetereocycles for the 





CHAPTER 4: CONCLUSION 
 
NO has been implicated in a wide variety of neurodegenerative disease states and 
inhibitors of NOS could have broad therapeutic potential in the treatment of these 
diseases. To date, the identification of potent and selective NOS inhibitors has been a 
subject of intense interest in the research field of NOS.[221] The search for potent and 
selective NOS inhibitors proved to be a challenging one as the topology of the 
respective isoforms of NOS are very much similar. It was revealed in SAR studies 
that the distance between the heme cofactor and the residues responsible for the 
recognition of L-amino acid are quite similar.[222] Therefore subtle structural changes 
of the substrate-binding sites of the NOS isoforms could be useful in directing 
rationale design of selective-isoform NOS inhibitors with great therapeutic 
potential.[43, 195, 197, 223]  
So far, most NOS inhibitors described in the literature have been developed based on 
inhibition of NOS enzymatic activity. These inhibitors can be further divided into 
those that target the L-Arg binding site (substrate-based) and also those that target the 
cofactor-binding sites (non-substrate-based). The majority of inhibitors that interfere 
with the substrate-binding site are L-Arg analogues, non-L-Arg-based amino acid 
analogues and guanidine-derivatives which are structurally different from L-Arg. The 
majority of inhibitors which target the cofactor-binding sites were non-selective, 
specific and/or potent. These non-substrate-based inhibitors do not distinguish 
effectively between the isoforms of NOS and may interfere with enzymatic activities 
of other enzymes which utilize similar cofactors, even though they might be potent 
and specific in their inhibition. On the other hand, substrate-based inhibitors were 
found to be more isoform selective as compared to the non-substrate-based inhibitors. 
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Library MK-I and MK-II compounds, which consisted of N1-α-substituted N1-
benzyl-N2-nitroguanidines, were synthesized based on lead compound I (N1-
diphenylmethyl-N2-nitroguanidine). A series of amines were synthesized with yields 
of 71 to 99% for coupling with SMNNITU to form library MK-I and MK-II 
compounds. The yields obtained for library MK-I and MK-II compounds ranged 
from 48 to 75% and 37 to 47% respectively. The synthesis of Library MK-I was 
relatively simple and straightforward whereas the synthesis of MK-II compounds 
required a longer period of time as a lot of functional group interconversions were 
involved. The optimization studies were tedious and time-consuming as purification 
via flash column chromatography was needed for almost every single step of the 
reaction scheme. Library MK-I and MK-II compounds were screened against the 
three NOS isoforms at 100µM. 
The N at the para position of the pyridinyl ring gave a higher inhibition of 36% for 
nNOS isoform as compared to the two isomers of pyridinyl rings for library MK-I. 
For the cyclo-hydrocarbon rings, as ring size increased (from cyclopropane to 
cyclopentane), the inhibition for nNOS isoform also increased. The percent inhibition 
for nNOS isoform was found to decrease to 29% when R1 was cyclohexane (MK-I-
07). This suggested that maximal inhibition of 39% was achieved by the cyclopentyl 
ring in the cyclo-hydrocarbon rings series.   
Both MK-I-08 and MK-I-09 were nNOS selective with inhibition of 83 to 120% 
against the nNOS isoform with respect to the L-NNA positive control. MK-I-08 had a 
naphthalene group which may be responsible for hydrophobic interaction at the active 
site, thereby giving rise to a high inhibition of 83%. MK-I-09 has a thiophene group 
which may be able to fit into the active site pocket thereby causing a strong inhibiton 
of 120% with respect to the positive control (100%), L-NG-nitro-arginine (L-NNA).  
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The results of these two compounds could give further insights into the hydrophobic 
interactions towards RegG of the NOS active site. 
From our study, a small library of nine MK-I compounds with various ring systems 
were synthesized. For MK-II compounds, only two compounds were synthesized. 
Therefore the objective to synthesize a series of MK-II compounds was not entirely 
met and more compounds have to be synthesized to make up a complete library for 
comparison of results. These eleven compounds (MK-I and MK-II) were screened 
for their inhibitory activities against the three isoforms of NOS at 100µM only. 
Further screenings using various concentrations would have to be done and the IC50 of 
the respective compounds have to be determined. From the screening results, it could 
be seen that the majority of library MK-I compounds and MK-II compounds gave 
some inhibition against the nNOS isoform. Unfortunately there was not enough data 
to prove that these compounds had better inhibitory actions as compared to I as they 
were screened only at 100µM. Therefore again, the objectives of determining the IC50 
and the isoform selectivity were partially met due to the screenings at 100µM only. 
Hence, further works would need to be done in order to achieve these objectives. 
Nevertheless, these compounds exhibit inhibition for the NOS isoforms, particularly 
towards the nNOS isoform and therefore, it would be worthwhile to pursue further in 
order to for a more conclusive comparison between the compounds and I.  
Another library of guanidino-containing hetereocycles (non-substrate-based NOS 
inhibitors) (III – X) was screened for their inhibitory activities against the neuronal 
isoform of NOS. Compound X was found to give the highest inhibition of 44% 
among the guanidino-containing hetereocycles screened at 100µM. This could be due 
to stronger interactions (e.g. hydrogen bonding) of the sulphur with the active site. 
Compounds X and XII were found to be very similar in structures to the BH4 
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inhibitors reported[161, 163]  and this suggested the possibility of non-substrate-based 
inhibition of X and XII. These results were only preliminary and futher screenings of 
the respective compounds could be done (i.e. respective IC50), for more conclusive 
comparison between the results as only one concentration (100µM) was screened for 
all the compounds. 
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CHAPTER 5: MATERIALS AND METHODS 
 
5.1 General Methods for Synthesis 
All solvents and reagents used in the synthesis were purchased from Sigma, Aldrich, 
Fluka, Merck and Lancaster. They were used without further purification unless stated 
otherwise. Merck silica gel 60 (230 – 400 mesh ASTM) was used for flash column 
chromatography. Thin-layer chromatography was carried out on E.Merck precoated 
silica gel 60 F254 plates. Compounds were visualized with ninhydrin stain, ceric 
ammonium molybdate stain or a UV/Vis lamp. 1H NMR and 13C NMR spectra were 
recorded on a Bruker DPX-300 spectrometer. Chemical shifts were reported as δ 
values in parts per million (ppm) downfield from TMS (δ = 0.0) as the internal 
standard in DMSO-d6, CDCl3 or CD3OD. IR analyses were performed on a Perkin 
Elmer Spectrum-100 FT-IR Spectrometer with KBr pressed disc. The MS spectra 
were obtained using a Finnagan LCQ Ion Trap MS Mass Spectrometer under 
electron-spray ionization (ESI) (solvent: 50% aqueous methanol) and the m/z ratios of 
[M+1]+ were reported. 
 
5.2 Synthesis of Library MK-I 
5.2.1 General procedure for synthesis of oximes 
A mixture of the phenone (10 mmol), and NH2OH.HCl (15 mmol) in 50ml of aqueous 
EtOH was stirred and treated with NaOH pellets (80 mmol) added in small portions. 
The resulting mixture was then heated at reflux. The mixture was cooled and the 
solvent removed via rotary evaporator. The residue was then dissolved in water and 
extracted 3 times with EA. The combined organic extracts were then washed with 
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brine and dried (Na2SO4). Evaporation of the solvent gave a solid (syn- and anti- 
isomers mixture).   
 
5.2.1.1 Phenyl(pyridin-2-yl)methanone Oxime (1-01). Yellow solid, (100%). 1H 
NMR (300 MHz, DMSO-d6) δ 11.64 (s, 1H, N-OH), 11.50 (s, 0.2H, N-OH), 8.66 (d, 
J = 4.5 Hz, 0.2H, pyridinyl-H), 8.47 (d, J = 4.5 Hz, 1H, pyridinyl-H),  7.93-7.82 (m, 
2H, pyridinyl-H), 7.53 (d, J = 3.8 Hz, 1H, Ar-H), 7.43-7.29 (m, 7H, Ar-H). 
 
5.2.1.2 Phenyl(pyridin-3-yl)methanone Oxime (1-02). Off-white solid, (91%). 1H 
NMR (300 MHz, DMSO-d6) δ 11.66 (s, 0.1H, N-OH), 11.63 (s, 0.9H, N-OH), 8.63 – 
8.58 (m, 1H, pyridinyl-H), 8.50 (br s, 1H, pyridinyl-H),  7.75-7.70 (m, 1H, pyridinyl-
H), 7.53-7.40 (m, 6H, Ar-H+pyridinyl-H). 
 
5.2.1.3 Phenyl(pyridin-4-yl)methanone Oxime (1-03). Yellow solid, (100%). 1H 
NMR (300 MHz, DMSO-d6) δ 12.14 (s, 0.4H, N-OH), 11.74 (s, 0.6H, N-OH), 8.74 (d, 
J = 2.4 Hz, 1H, pyridinyl-H), 8.65 (d, J = 2.4 Hz, 0.6H, pyridinyl-H),  7.51-7.31 (m, 
7H, Ar-H+pyridinyl-H). 
 
5.2.1.4 Cyclopropyl(phenyl)methanone Oxime (1-04). White solid, (100%). 1H 
NMR (300 MHz, DMSO-d6) δ 10.99 (s, 0.7H, N-OH), 10.50 (s, 0.3H, N-OH), 7.42-
7.34 (m, 5H, Ar-H), 2.21-2.12 (m, 0.7H, cyclopropyl-H),  1.77-1.66 (m, 0.4H, 
cyclopropyl-H), 0.90-0.64 (m, 3H, cyclopropyl-H), 0.52-0.47 (m, 1H, cyclopropyl-H). 
 
5.2.1.5 Cyclobutyl(phenyl)methanone Oxime (1-05). White solid, (88%). 1H NMR 
(300 MHz, DMSO-d6) δ 10.91 (s, 0.6H, N-OH), 10.62 (s, 0.3H, N-OH), 7.38-7.30 (m, 
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5H, Ar-H), 3.81-3.69 (m, 0.6H, cyclobutyl-H), 3.48-3.39 (m, 0.4H, cyclobutyl-H), 
3.34-1.56 (m, 6H, cyclobutyl-H). 
 
5.2.1.6 Cyclopentyl(phenyl)methanone Oxime (1-06). Off-white solid, (88%). 1H 
NMR (300 MHz, DMSO-d6) δ 11.02 (s, 0.6H, N-OH), 10.45 (s, 0.3H, N-OH), 7.40-
7.26 (m, 5H, Ar-H), 3.48-3.42 (m, 0.7H, cyclopentyl-H), 2.96-2.94 (m, 0.4H, 
cyclopentyl-H), 1.87-1.57 (m, 8H, cyclopentyl-H). 
 
5.2.1.7 Cyclohexyl(phenyl)methanone Oxime (1-07). White solid, (100%). 1H NMR 
(300 MHz, DMSO-d6) δ 10.97 (s, 0.7H, N-OH), 10.44 (s, 0.9H, N-OH), 7.40-7.21 (m, 
9H, Ar-H), 3.22-3.14 (m, 0.1H, cyclohexyl-H), 2.45 (br s, 0.8H, cyclohexyl-H), 1.72-
1.11 (m, 20H, cyclopentyl-H). 
 
5.2.1.8 (Naphthalen-3-yl)(phenyl)methanone Oxime (1-08). Pale-yellow solid, 
(100%). 1H NMR (300 MHz, DMSO-d6) δ 11.44 (br s, 1H, N-OH), 8.00-7.80 (m, 3H, 
Ar-H), 7.61-7.34 (m, 9H, Ar-H). 
 
5.2.1.9 Phenyl(thiophen-3-yl)methanone Oxime (1-09). Yellow solid, (100%). 1H 
NMR (300 MHz, DMSO-d6) δ 12.22 (br s, 0.8H, N-OH), 11.29 (s, 0.2H, N-OH), 
7.81-7.80 (m, 0.8H, Ar-H), 7.52 (s, 5H, Ar-H),  7.38-7.35 (m, 0.6H, Ar-H), 7.12-7.09 
(m, 2H, thiol-H), 7.02-6.99 (m, 0.3H, thiol-H), 6.71 (d, J = 1.7 Hz, 0.3H, thiol-H). 
 
5.2.2 General procedure for reduction of oximes to amines 
To a solution of oxime (2.5 mmol) in MeOH (25 ml) was added ammonium formate 
(4 mmol) and zinc powder (10 mmol) with stirring in a round bottom flask. The 
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reaction mixture was then allowed to go to reflux. After the reaction was cooled, the 
zinc powder was then filtered off. The filtrate was then subjected to rotary evaporator 
to remove the MeOH. 25% ammonium solution was then added to the residue and 
extracted 3 times with DCM. The organic layer was then acidified with conc. HCl and 
extracted with H2O. The aqueous layer was then re-basified with 1N NaOH and 
extracted 3 times with DCM. The combined organic extracts were then washed with 
brine and dried (Na2SO4). Evaporation of the solvent gave typically a liquid (racemic 
mixture).   
 
5.2.2.1 Phenyl(pyridin-2-yl)methanamine (1-10). Off-white solid, (80%). 1H NMR 
(300 MHz, DMSO-d6) δ 8.60 (br s, 1H, Ar-H), 11.50 (s, 0.2H, N-OH), 8.66 (d, J = 4.5 
Hz, 0.2H, pyridinyl-H), 8.47 (d, J = 4.5 Hz, 1H, pyridinyl-H),  7.93-7.82 (m, 2H, 
pyridinyl-H), 7.53 (d, J = 3.8 Hz, 1H, Ar-H), 7.43-7.29 (m, 7H, Ar-H). 
 
5.2.2.2 Phenyl(pyridin-3-yl)methanamine (1-11). Yellow liquid, (93%). 1H NMR 
(300 MHz, DMSO-d6) δ 8.61 (br s, 1H, pyridinyl-H), 8.39 (dd, Jdd = 0.005 Hz, Jd = 
0.0163 Hz, 1H, pyridinyl-H), 7.78 (d, J = 4.0 Hz, 1H, pyridinyl-H), 7.43-7.17 (m, 6H, 
pyridinyl-H+Ar-H). 13C NMR (75 MHz, DMSO-d6) δ 148.5, 147.8, 146.1, 142.2, 
134.6, 128.6, 126.9, 123.7, 57.0.  
 
5.2.2.3 Phenyl(pyridin-4-yl)methanamine (1-12). Yellow liquid, (99%). 1H NMR 
(300 MHz, DMSO-d6) δ 8.46 (d, 2H, pyridinyl-H), 7.41-7.17 (m, 7H, pyridinyl-
H+Ar-H), 5.07 (s, 1H, benzylic-H), 2.40 (br s, 2H, N-H). 13C NMR ( 75 MHz, 
DMSO-d6) δ 155.6, 149.6, 145.6, 128.6, 127.1, 122.3, 58.4.  
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5.2.2.4 Cyclopropyl(phenyl)methamine (1-13). Pale yellow liquid, (86%). 1H NMR 
(300 MHz, DMSO-d6) δ 7.40-7.17 (m, 5H, Ar-H), 3.17 (d, J = 4.0 Hz, 1H, benzylic-
H), 1.76 (br s, 2H, N-H), 1.15-0.89 (m, 1H, cyclopropyl-H), 0.54-0.20 (m, 4H, 
cyclopropyl-H). 13C NMR ( 75 MHz, DMSO-d6) δ 146.8, 128.3, 126.7, 59.7, 20.2, 3.9, 
3.1.  
5.2.2.5 Cyclobutyl(phenyl)methamine (1-14). Clear colorless liquid, (81%). 1H 
NMR (300 MHz, DMSO-d6) δ 7.31-7.15 (m, 5H, Ar-H), 3.65 (d, J = 4.4 Hz 1H, 
benzylic-H), 3.32 (br s, 2H, N-H), 2.43-2.29 (m, 11H, cyclobutyl-H), 2.02-1.56 (m, 
6H, cyclobutyl-H). 
 
5.2.2.6 Cyclopentyl(phenyl)methamine (1-15). Clear colorless liquid, (78%). 1H 
NMR (300 MHz, DMSO-d6) δ 7.32-7.15 (m, 5H, Ar-H), 3.50 (d, J = 4.4 Hz 1H, 
benzylic-H), 2.27-1.01 (m, 11H, cyclopentyl-H+N-H).  
 
5.2.2.7 Cyclohexyl(phenyl)methamine (1-16). Clear colorless liquid, (92%). 1H 
NMR (300 MHz, DMSO-d6) δ 7.30-7.16 (m, 5H, Ar-H), 3.50 (d, J = 3.4 Hz 1H, 
benzylic-H), 3.30 (br s, 2H, N-H), 1.92-0.76 (m, 11H, cyclohexyl-H). 13C NMR (75 
MHz, DMSO-d6) δ 146.1, 128.1, 127.4, 126.6, 61.0, 45.0, 29.8, 29.2, 26.4, 26.1. 
 
5.2.2.8 (Naphthalen-3-yl)(phenyl)methamine (1-17). Yellow liquid, (71%). 1H 
NMR (300 MHz, DMSO-d6) δ 7.95 (s, 1H, Ar-H), 7.87-7.78 (m, 3H, Ar-H), 7.51-




5.2.2.9 Phenyl(thiophen-3-yl)methamine (1-18). Yellow liquid, (83%). 1H NMR 
(300 MHz, DMSO-d6) δ 7.43-7.21 (m, 6H, thiol-H+Ar-H), 6.90-6.84 (m, 2H, thiol-H), 
5.30 (s, 1H, benzylic-H). 13C NMR (75 MHz, DMSO-d6) δ 152.0, 146.4, 128.6, 127.2, 
126.9, 124.6, 123.8, 55.5. 
 
5.2.3 Synthesis of S-methyl-N-nitroisothiourea (SMNNITU).  S-methylisothiourea 
sulphate (SMITUSO4, 20 g) was added slowly over 5 minutes to a mixture of fuming 
nitric acid (20 ml) and concentrated sulphuric acid (60 ml) in an ice-bath.  After 
continuous stirring for another 15 minutes, the reaction mixture was poured slowly 
into a beaker of ice (850 g).  The white precipitate formed was collected by vacuum 
filtration after the ice had melted.  Two recrystallisations from aqueous ethanol 
afforded clear, white needle crystals (50 – 60 % yield): mp 161 – 163 °C (ref.198 163 – 
164 °C); 1H NMR (DMSO-d6) δ 9.13 (b, 2H, NH), 2.41 (s, 3H, CH) ppm; MS (ESI) 
(m/z): [M + 1]+ 136.1. 
 
5.2.4 General procedure for coupling of amines with S-methyl-N-nitroisothiourea 
The amine and SMNNITU (1:1) was charged into a round bottom flask with stirring 
and heated for 30mins at 85oC. As the reaction progressed, bubbles were observed 
and the reaction mixture turned into a foamy solid. TLC analysis of the foamy solid 
still showed presence of starting materials. EtOH was then added and the reaction 
mixture was allowed to stir at room temperature overnight. The ethanol was then 
removed and purification of the crude mixture via column chromatography 










5.2.4.1 Nitro-3-(phenyl(pyridin-2-yl)methyl)guanidine (MK-I-1). Yellow-green 
solid, (48%). 1H NMR (300 MHz, DMSO-d6) δ 8.59 (d, J = 4.5 Hz, 1H, Ar-H), 8.08 
(br s, 1H, NH), 7.84 (m, 1H, Ar-H), 7.51-7.24 (m, 7H, Ar-H), 6.15 (d, J = 7.9 Hz, 1H, 
benzylic H); 13C NMR ( 75 MHz, DMSO-d6) 135.7, 128.2, 118.8, 111.8, 111.7, 110.7, 
110.1, 107.0, 106.4, 54.8. IR (KBr disc) 3373, 3313, 3155, 1649, 1630, 1595, 1312, 
766, 697, 562 cm-1. MS (ESI) (m/z): [M + 1]+ calcd for C13H13N5O2 272.1, found 
272.2. 
 
5.2.4.2 Nitro-3-(phenyl(pyridin-3-yl)methyl)guanidine (MK-I-2). Off-white solid, 
(50%). 1H NMR (300 MHz, DMSO-d6) δ 8.58 (m, 2H, Ar-H), 7.80 (br s, 1H, NH), 
7.61 (d, J = 7.8 Hz,  1H, Ar-H) 7.36 (m, 6H, Ar-H) 6.59 (br s, 1H, NH), 5.94 (s, 1H, 
benzylic H); 13C NMR ( 75 MHz, DMSO-d6) 158.6, 149.9, 140.1, 128.9, 128.0, 127.5, 
121.9, 56.9. IR (KBr disc) 3431, 3324, 3250, 1634, 1454, 1260, 716, 701, 582, 528 
cm-1. MS (ESI) (m/z): [M + 1]+ calcd for C13H13N5O2 272.1, found 272.2. 
 
5.2.4.3 Nitro-3-(phenyl(pyridin-4-yl)methyl)guanidine (MK-I-3). Yellow foamy 
solid, (70%). 1H NMR (300 MHz, DMSO-d6) δ 8.53 (d, J = 5.4 Hz, 2H, Ar-H), 7.24 
(m, 7H, Ar-H+CDCl3), 5.94 (s, 1H, benzylic H); 13C NMR ( 75 MHz, DMSO-d6) 
140.6, 137.0, 134.7, 128.8, 127.8, 127.1, 123.7 55.6. IR (KBr disc) 3408, 3309, 3061, 
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3032, 1626, 1266, 700, 641 cm-1. MS (ESI) (m/z): [M + 1]+ calcd for C13H13N5O2 
272.1, found 272.1. 
 
5.2.4.4 (Cyclopropyl(phenyl)methyl)-3-nitroguanidine (MK-I-4). White solid, 
(70%). 1H NMR (300 MHz, DMSO-d6) δ 8.45 (br s, 1H, NH), 7.26 (m, 5H, Ar-
H+CDCl3), 6.51 (br s, 1H, NH), 3.85 (br s, 1H, benzylic H), 1.20 (m, 1H, cyclopropyl 
H), 0.55 (m, 2H, cyclopropyl H), 0.47 (m, 2H, cyclopropyl H); 13C NMR ( 75 MHz, 
CDCl3) δ 158.9, 138.6, 129.3, 128.6, 126.6, 126.2, 61.3, 17.9, 4.3, 3.6; IR (KBr disc) 
3412, 3307, 3085, 3030, 3005, 1626, 1264, 700, 562 cm-1. MS (ESI) (m/z): [M + 1]+ 
calcd for  C11H14N4O2 235.1, found 235.0. 
 
5.2.4.5 (Cyclobutyl(phenyl)methyl)-3-nitroguanidine (MK-I-5). White solid, 
(40%). 1H NMR (300 MHz, CDCl3) δ 8.45 (br s, 1H, NH), 7.35 (m, 5H, Ar-
H+CDCl3), 6.48 (br s, 1H, NH) 4.33 (br s, 1H, benzylic H), 2.67 (m, 1H, cyclobutyl 
H), 2.14 (m, 1H, cyclobutyl H), 1.84 (br s, 5H, cyclobutyl H); 13C NMR ( 75 MHz, 
CDCl3) δ 159.4, 137.9, 129.4, 128.7, 126.2, 62.1, 41.1, 25.61, 25.0, 17.3; IR (KBr 
disc) 3492, 3275, 3151, 2948, 1631, 1591, 1435, 1230, 1089, 703, 553 cm-1. MS (ESI) 
(m/z): [M + 1]+ calcd for C12H16N4O2 249.1, found 249.2. 
 
5.2.4.6 (Cyclopentyl(phenyl)methyl)-3-nitroguanidine (MK-I-6). White solid, 
(69%). 1H NMR (300 MHz, DMSO-d6) δ IR (KBr disc) δ 8.22 (br s, 1H, NH), 7.35 
(m, 5H, Ar-H+CDCl3), 4.15 (m, 1H, benzylic H), 2.26 (m, 1H, cyclopentyl H), 1.92 
(m, 1H, cyclopentyl H), 1.44 (m, 7H, cyclopentyl H+ residual H2O); 13C NMR ( 75 
MHz, DMSO-d6) 158.8, 142.6, 141.6, 128.4, 127.3, 126.9, 58.9, 45.3, 29.7, 24.8. IR 
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(KBr disc) 3493, 3275, 3150, 2948, 1631, 1580, 1434, 1230, 1089, 785, 704, 553 cm-1.    
MS (ESI) (m/z): [M + 1]+ calcd for C13H18N4O2 263.1, found 263.2.  
 
5.2.4.7 (Cyclohexyl(phenyl)methyl)-3-nitroguanidine (MK-I-7). White solid, 
(70%). 1H NMR (300 MHz, DMSO-d6) δ 8.94 (br s, 1H, NH), 7.39 (m, 3H, Ar-H), 
7.25 (m, 2H, Ar-H) 5.96 (br s, 1H, NH), 4.15 (t, J = 6.3 Hz, 1H, benzylic H), 1.47 (m, 
11H, cyclohexyl H+residual H2O); 13C NMR ( 75 MHz, DMSO-d6) 159.1, 140.4, 
128.3, 127.1, 59.3, 42.2, 29.5, 29.2, 25.8, 25.2.  IR (KBr disc) 3380, 3307, 3171, 3030, 
2929, 2859, 1646, 1593, 1245, 700, 585 cm-1. MS (ESI) (m/z): [M + 1]+ calcd for 
C14H20N4O2 277.2, found 277.2. 
 
5.2.4.8 ((Naphthalen-3-yl)(phenyl)methyl)-3-nitroguanidine (MK-I-8). White solid, 
(70%). 1H NMR (300 MHz, DMSO-d6) δ 7.85 (m, 4H, Ar-H), 7.54 (m, 2H, Ar-H), 
7.38 (m, 6H, Ar-H), 5.87 (d, J = 4.8 Hz, 1H, benzylic H); 13C NMR ( 75 MHz, 
DMSO-d6) 158.6, 141.4, 141.2, 133.7, 132.2, 128.7, 128.4, 127.8, 127.6, 127.3, 126.5, 
126.2, 125.4, 125.3, 57.7. IR (KBr disc) 3431, 3321, 1634, 1518, 1453, 1259, 817, 
736, 701, 571 cm-1. MS (ESI) (m/z): [M + 1]+ calcd for C18H16N4O2 321.1, found 
321.1. 
 
5.2.4.9 Nitro-3-(phenyl(thiophen-3-yl)methyl)guanidine (MK-I-9). Pale-yellow 
solid, (75%). 1H NMR (300 MHz, DMSO-d6) δ 7.86 (br s, 1H, NH), 7.43 (m, 5H, Ar-
H), 7. 33 (d, J = 5.1 Hz, 1H, thiophene H), 6.93 (m, 2H, thiophene H), 6.37 (br s, 1H, 
NH), 5.97 (d, J = 5.1 1H, benzylic H); 13C NMR ( 75 MHz, CD3OD) 160.1, 146.0, 
141.9, 129.8, 129.2, 128.1, 127.9, 127.1, 126.7, 55.7. IR (KBr disc) 3424, 3316, 1633, 
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1514, 1465, 1260, 701, 592 cm-1. MS (ESI) (m/z): [M + 1]+ calcd for C12H12N4O2S 
277.1, found 276.9. 
 
5.3 Synthesis of Library MK-II 
5.3.1 Phenyl(m-tolyl)methanamine (2-01). Lithium wire (0.22 g, 25 mmol) was 
placed in a 2-neck round bottom flask covered with anhydrous diethyl ether (DEE) 
(20 ml) and fitted with a condenser under N2. A few drops of bromobenzene were 
added to initiate the reaction. The reaction mixture was then placed under an ice-bath 
and the remaining bromobenzene (1.05 mL, 10 mmol) was added dropwise with 
vigorous stirring, and the mixture kept below its boiling point. The reaction is 
completed when the lithium disappears. m-tolunitrile (1.68 mL, 14 mmol) was added 
dropwise to the reaction mixture and stirred under N2 at -75oC. The reaction was 
monitored via TLC for completion. BACH-EI (7.7 mL, 15.4 mmol) was then added 
dropwise to the reaction mixture at 0oC with stirring under N2. The reaction was 
monitored via TLC for completion. The reaction mixture was quenched with water at 
0oC and the solvent was removed via rotary evaporatory. The resultant salt was re-
dissolved in water and pH was adjusted > 11. The reaction mixture was then stirred 
and then extracted 3 times with ether. The combined organic extracts were then 
washed with brine and dried with anhydrous sodium sulphate (Na2SO4). The solution 
was concentrated in vacuo, and the residue was purified by flash column 
chromatography (DCM/MeOH/TEA = 10:1:0.1, Rf = 0.30) to afford 2-01 (0.82g, 30%) 
as a yellow viscous liquid. 1H NMR (300 MHz, DMSO-d6) δ 7.40-7.12 (m, 8H, Ar-H), 
6.97 (d, J = 3.8 Hz, 1H, Ar-H), 5.03 (s, 1H, benzylic-H), 2.3 (s, 3H, methyl-H). 13C 
NMR (75 MHz, DMSO-d6) δ 146.9, 146.8, 137.1, 128.1, 128.0, 127.3, 127.0, 126.7, 
126.3, 59.2, 21.1. 
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5.3.2 Tert-butyl phenyl(m-tolyl)methylcarbamate (2-02). To a solution of 2-01 
(0.63 g, 3.2 mmol) in dichloromethane (DCM, 5 mL) was added di-tert-butyl 
dicarbonate (0.73 mL, 3.2 mmol). The reaction was monitored via TLC for 
completion. The reaction mixture was then diluted with DCM (20 mL) and washed 
with 0.5 N HCl, brine and then dried (Na2SO4). The solvent was removed and 2-02 
(0.85 g, 89%) was obtained as a yellow solid (>99% purity as confirmed via NMR 
spectroscopy). 1H NMR (300 MHz, DMSO-d6) δ 7.89 (d, J = 9.03 Hz, 1H, N-H), 
7.30-7.01 (m, 9H, Ar-H), 5.76 (d, 1H, benzylic-H), 2.26 (s, 3H, methyl-H), 1.39 (s, 
9H, Boc-H). 13C NMR (75 MHz, DMSO-d6) δ 155.6, 143.3, 143.2, 137.9, 128.8, 
128.7, 128.0, 127.7, 127.4, 127.3, 127.1, 124.6, 78.9, 58.1, 28.6, 28.4, 21.5. 
 
5.3.3 Tert-butyl bromo(phenyl)(m-tolyl)methylcarbamate (2-03). To a solution of 
2-02 (0.30 g, 1 mmol) in CCl4 (4 mL) was added N-bromosuccinimide (0.19 g, 1.05 
mmol) and refluxed. The reaction was initiated by shining a 100W lamp for 15 
minutes. The reaction progress was monitored via TLC. The completed reaction 
mixture was then cooled and filtered to remove any excess N-bromosuccinimide and 
succinimide (side-product). The filtrate was then evaporated. The residue was 
dissolved in EA, washed with cold 5% aqueous NaOH, H2O, brine and dried (Na2SO4) 
to give crude 2-03. Crude 2-03 was purified via flash column chromatography 
(Hexane/EA = 15:1, Rf = 0.30) to afford pure 2-03 (0.36 g, 80%) as a yellow solid. 1H 
NMR (300 MHz, DMSO-d6) δ 7.54-7.16 (m, 9H, Ar-H), 2.34 (s, 3H, methyl-H), 1.23 
(s, 9H, Boc-H).  
 
5.3.4 m-Cyanobenzyl bromide (3-01).  To a solution of m-toluonitrile (1.2 ml, 10 
mmol) in CCl4 (5 mL) was added N-bromosuccinimide (1.78 g, 10 mmol) and 
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refluxed. The reaction was initiated by shining a 100W lamp for 15 minutes. The 
reaction progress was monitored via TLC. The completed reaction mixture was then 
cooled and filtered to remove any excess N-bromosuccinimide and succinimide (side-
product). The filtrate was then evaporated and recrystallized from ethanol to afford 3-
01 (1.73 g, 88%) as white crystals. 1H NMR (300 MHz, DMSO-d6) δ 7.94 (s, 1H, Ar-
H), 7.80 (d, J = 7.5 Hz, 2H, Ar-H), 7.59 (t, 1H, Ar-H), 4.74 (s, 1H, benzylic-H).  
 
5.3.5 m-Cyanobenzaldehyde (3-02). A suspension of 3-01 (0.98 g, 5 mmol) and 
hexamine (1.40 g, 10 mmol) in chloroform (10 mL) was refluxed for 3 hours. The 
solvent was concentrated in vacuo and 50% aq. Acetic acid (50 mL) was added. The 
reaction was allow to reflux for 2 hours. The aq. Acetic acid was removed in vacuo 
and the residue dissolved in H2O and was extracted 3 times with EA (30 mL). The 
combined organic extracts were then washed with sat. NaHCO3 and dried (Na2SO4). 
The solvent was removed in vacuo and the residue was recrystallized in EtOH to give 
3-02 (0.59 g, 90%) as pale yellow needles. 1H NMR (300 MHz, DMSO-d6) δ 10.05 (s, 
1H, aldehyde-H), 8.38 (s, 1H, Ar-H), 8.23-8.17 (m, 2H, Ar-H), 7.85-7.72 (m, 2H, Ar-
H). 13C NMR (75 MHz, DMSO-d6) δ 191.8, 137.5, 136.7, 133.5, 133.3, 130.5, 117.9, 
112.3. 
 
5.3.6 m-Cyanobenzyl alcohol (3-03). A 13% aqueous acidic TiCl3 solution (2 mL, 
0.86 mmol) was added dropwise at 0oC under N2 to a well-stirred solution of 3-02 
(0.11 g, 0.84 mmol) in MeOH (5 mL) and ~25% wt ammonia solution (2 mL). After 
additional stirring (5 mins) at room temperature, the resulting suspension was diluted 
with H2O and extracted with EA. The combined organic extracts were washed with 
H2O and dried (Na2SO4). The solvent was concentrated in vacuo and the residue was 
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subjected to flash column chromatography (Hexane/EA = 2:1, Rf = 0.32) to afford 3-
03 (0.11 g, 96%) as a bright yellow viscous liquid. The  1H NMR (300 MHz, DMSO-
d6) δ 7.74-7.66 (m, 3H, Ar-H), 7.57-7.52 (m, 1H, Ar-H), 5.46 (t, J = 5.7 Hz, 1H, O-H), 
4.56 (d, J = 4.9 Hz, 2H, benzylic-H).  13C NMR (75 MHz, DMSO-d6) δ 144.3, 131.4, 
130.7, 129.9, 129.6, 119.2, 111.2, 61.9.  
 
5.3.7 3-((Tetrahydro-2H-pyran-2-yloxy)methyl)benzonitrile (3-04). A solution of 
3-03 (5.01 g, 38.2 mmol) and dihydropyran (3.8 mL, 45.2 mmol) in DCM (25 mL) 
was cooled to 0oC under N2. p-Toluenesulfonic acid monohydrate (catalytic amount) 
was then added and the reaction was allowed to stir at room temperature for 2 hours. 
The reaction mixture was diluted with DCM (20 mL) washed with sat. NaHCO3, 
brine and dried (Na2SO4). The solvent was removed in vacuo and the residue was 
subjected to flash column chromatography (Hexane/EA = 8:1, Rf = 0.33) to afford 3-
04 (4.07 g, 49%) as a clear yellow viscous liquid. 1H NMR (300 MHz, DMSO-d6) δ 
7.79-7.69 (m, 3H, Ar-H), 7.60-7.55 (m, 1H, Ar-H), 4.72 (d, J = 12.4 Hz, 2H, 
benzylic-H), 4.52 (d, J = 12.8 Hz, 1H, THP-H), 3.80-3.74 (m, 1H, THP-H), 3.51-3.46 
(m, 1H, THP-H), 1.74-1.49 (m, 6H, THP-H). 13C NMR (75 MHz, DMSO-d6) δ 140.2, 
132.2, 131.2, 130.7, 129.5, 118.8, 111.2, 97.6, 67.0, 61.3, 30.1, 24.9, 19.0. 
 
5.3.8 α-Phenyl(m-aminomethyl) benzyl alcohol (3-05). Using the procedure 
described for the preparation of 2-01, compound 3-05 was obtained from 3-04 as a  
clear yellow solution (0.15 g, 42%). 1H NMR (300 MHz, DMSO-d6) δ 7.40-7.10 (m, 
9H, Ar-H), 5.13-5.09 (m, 2H, O-H+benzylic-H from NH2), 4.44 (d, J = 4.5 Hz, 2H, 
benzylic-H from OH)  13C NMR (75 MHz, DMSO-d6) δ 146.8, 146.5, 142.3, 128.1, 
127.8, 126.7, 126.3, 125.1, 124.8, 124.6, 63.0, 59.3. 
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5.3.9 N-Boc-α-Phenyl(m-aminomethyl) benzyl alcohol (3-06). Using the procedure 
described for the preparation of 2-02, compound 3-06 was obtained from 3-05 as a  
clear viscous liquid (0.20 g, 91%). 1H NMR (300 MHz, DMSO-d6) δ 13C NMR (75 
MHz, DMSO-d6) δ 7.93 (d, 1H, N-H), 7.31-7.15 (m, 9H, Ar-H), 5.81-5.75 (m, 1H, O-
H), 5.14 (br s, 1H, benzylic-H from N-H), 4.45 (s, 2H, benzylic-H from OH), 1.39 (s, 
9H, Boc-H). 13C NMR (75 MHz, DMSO-d6) δ 155.3, 143.1, 142.9, 142.6, 128.5, 
128.3, 127.3, 127.0, 125.7, 125.4, 125.3, 78.5, 63.1, 63.0, 58.0, 31.4, 31.3, 28.4. 
 
5.3.10 N-Boc-α-Phenyl(m-aminomethyl) benzyl chloride (3-07). To a stirred 
solution of 3-06 (0.20 g, 0.64 mmol) and triphenylphosphine (0.17 g, 0.64 mmol) in 
CCl4 was added thionyl chloride (SOCl2, 0.06 mL, 0.89 mmol) at 0oC. The reaction 
mixture was then allowed to stir at room temperature. The reaction was monitored by 
TLC for completion. The reaction mixture was then filtered and washed with CCl4. 
The solvent was removed in vacuo and the residue was subjected to flash column 
chromatography (Hexane/EA = 5:1, Rf = 0.40) to afford 3-07 (0.15 g, 71%) as a pale 
yellow solid. 1H NMR (300 MHz, DMSO-d6) δ 7.98 (d, J = 4.3 Hz, 1H, N-H), 7.39-
7.22 (m, 9H, Ar-H), 5.82, (d, J = 9.4 Hz, 1H, benzylic-H from N-H), 4.72 (s, 2H, 
benzylic-H from Cl), 1.39 (s, 9H, Boc-H). 13C NMR (75 MHz, DMSO-d6) δ 155.0, 
143.5, 142.6, 137.5, 128.6, 128.2, 127.4, 127.3, 127.1, 127.0, 126.8, 78.1, 57.6, 46.1, 
28.2. 
 
5.3.11 N-Boc-α-Phenyl(m-aminomethyl) benzyl nitrile (3-08). To a solution of 3-07 
(0.15 g, 0.45 mmol) in 95% EtOH (3.5 mL) was added sodium cyanide, (NaCN, 0.04 
g, 0.76 mmol). The reaction mixture was then allowed to be heated to reflux. The 
reaction was monitored via TLC for completion. The pH of the reaction was basified 
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to > 14 and diluted with H2O and washed with ether. The combined organic extracts 
were then washed with sat. NaHCO3 and dried (Na2SO4). The solvent was removed in 
vacuo and the residue was subjected to flash column chromatography (Hexane/EA = 
8:1, Rf = 0.35) to afford 3-08 (0.13 g, 90%) as a pale yellow solid. 1H NMR (300 
MHz, CDCl3) δ 7.26-7.05 (m, 9H, Ar-H+CDCl3), 5.82 (br s, 1H, N-H), 5.09 (br s, 1H, 
benzylic-H from N-H), 4.39 (s, 2H, benzylic-H from CN), 1.36 (s, 9H, Boc-H). 13C 
NMR (75 MHz, CDCl3) δ 155.0, 142.2, 142.1, 139.0, 128.6, 128.5, 127.3, 127.2, 
126.6, 126.4, 79.8, 72.5, 65.8, 58.4, 28.3, 15.2. 
 
5.3.12 m-Benzoyl benzoic acid oxime (4-01). A mixture of’ 3-Benzoyl benzoic acid 
(10 mmol), and hydroxylamine hydrochloride (NH2OH.HCl, 15 mmol) in 50ml of 
aqueous EtOH was stirred and treated with sodium hydroxide (NaOH) pellets (80 
mmol) added in small portions. The resulting mixture was then heated at reflux for 2.5 
hours. The mixture was cooled and the solvent removed via rotary evaporator. The 
residue was then dissolved in water, acidified to pH < 1 and extracted 3 times with 
EA. The combined organic extracts were then washed with brine and dried (Na2SO4). 
Evaporation of the solvent afforded 4-01 a beige solid (99%). 1H NMR (300 MHz, 
DMSO-d6) δ 12.97 (br s, 1H, N-O-H), 11.51 (s, 1.6H, COO-H), 8.02-7.31 (m, 15H, 
Ar-H). 13C NMR (75 MHz, DMSO-d6) δ 167.0, 154.4, 137.1, 136.4, 133.7, 133.4, 
133.1, 131.0, 130.7, 129.7, 129.6, 129.1, 128.9, 128.6, 128.5, 128.3, 127.0.  
 
5.3.12 α-Phenyl(m-aminomethyl)benzoic acid hydrochloride (4-02). To a solution 
of 4-01 (2.5 mmol) in MeOH (25 ml) was added ammonium formate (4 mmol) and 
zinc powder (10 mmol) with stirring. The reaction mixture was then allowed to go to 
reflux overnight. After the reaction was cooled, the zinc powder was then filtered off. 
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The filtrate was then subjected to rotary evaporator to remove the MeOH. The filtrate 
was then acidified with 6N HCl. The aqueous layer was then removed in vacuo to 
afford 4-02 as an off-white solid (99%). 1H NMR (300 MHz, DMSO-d6) δ 9.03 (s, 1H, 
COO-H), 8.13 (s, 1H, Ar-H), 7.95 (d, J = 7.9 Hz, 1H, Ar-H), 7.74 (d, J = 7.9 Hz, 1H, 
Ar-H), 7.62-7.37 (m, 6H, Ar-H), 5.82 (d, J = 3.0 Hz, 1H, benzylic H). 13C NMR (75 
MHz, DMSO-d6) δ 166.9, 138.7, 137.8, 131.9, 131.4, 129.3, 129.1, 128.6, 128.1, 
127.3, 56.5. 
 
5.3.13 α-Phenyl(m-aminomethyl) benzyl alcohol (4-03). To a solution of 4-02 (0.27 
g, 1.02 mmol) in anhydrous tetrahydrofuran (THF, 10 mL) was added dropwise 
BACH-EI (0.57 mL, 1.13 mmol) at 0oC. The reaction was allowed to go to reflux for 
2 hours. Water was added dropwise to quench the reaction. THF was removed in 
vacuo and the residue was diluted with H2O pH basified to > 11 and extracted 3 times 
with DEE. The combined organic extracts were then washed with brine and dried 
(Na2SO4). The solvent was removed in vacuo and the residue was subjected to flash 
column chromatography (DCM/MeOH/TEA = 10:1:0.5%, Rf = 0.35) to afford 4-03 
(0.17 g, 80%) as an off-white solid. 1H NMR (300 MHz, DMSO-d6) δ 7.40-7.10 (m, 
9H, Ar-H), 5.13-5.09 (m, 2H, O-H+benzylic-H from NH2), 4.44 (d, J = 4.5 Hz, 2H, 
benzylic-H from OH). 13C NMR (75 MHz, DMSO-d6) δ 146.8, 146.5, 142.3, 128.1, 
127.8, 126.7, 126.3, 125.1, 124.8, 124.6, 63.0, 59.3. 
 
5.3.14 α-Phenyl(m-aminomethyl) benzyl chloride hydrochloride (4-04). To a 
solution of 4-03 (1.90 g, 8.9 mmol) in chloroform (CHCl3, 50 mL) was added SOCl2 
(3.23 mL, 44.5 mmol) drop wise. The reaction was then allowed to reflux for 25 
minutes. The precipitate formed was then filtered and washed with CHCl3 to afford 4-
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04 (2.00 g, 84%) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ 9.04 (br s, 3H, 
NH2+HCl), 7.50-7.34 (m, 9H, Ar-H), 5.68 (s, 1H, benzylic-H from N-H), 4.76 (s, 2H, 
benzylic-H from Cl). 13C NMR (75 MHz, DMSO-d6) δ 138.8, 138.2, 138.1, 129.2, 
128.8, 128.4, 127.8, 127.3, 127.2, 56.8, 45.8. 
 
5.3.15 α-Phenyl(m-aminomethyl) benzyl nitrile (4-05). To a solution of 4-04 (2.56 
g, 9.5 mmol) in DMF (50 mL) was added NaCN (1.40 g, 28.6 mmol). The reaction 
was allowed to stir at room temperature overnight. The reaction was diluted with H2O 
(50 mL) and extracted 3 times with DCM. The combined organic extracts were then 
washed with brine and dried (Na2SO4). The solvent was removed in vacuo and the 
residue was subjected to flash column chromatography (DCM/MeOH/TEA = 50:1:0.1, 
Rf = 0.35) to afford 4-05 (1.20 g, 57%) as a yellow viscous liquid. 1H NMR (300 MHz, 
DMSO-d6) δ 7.40-7.15 (m, 9H, Ar-H), 5.10 (s, 1H, benzylic-H from NH2), 3.99 (s, 
2H, benzylic-H from CN). 13C NMR (75 MHz, DMSO-d6) δ 147.7, 146.6, 131.0, 
128.7, 128.1, 126.7, 126.4, 126.1, 119.3, 59.0, 22.4. 
 
5.3.16 α-Phenyl(m-aminomethyl)acetic acid hydrochloride (4-06). 6N HCl (20 mL) 
was added to 4-05 (0.10 g, 0.45 mmol) and stirred at reflux for 4.5 hours. The reaction 
mixture was then extracted with DCM. The aqueous layer was removed in vacuo to 
afford 4-06 (0.11 g, 100%) as a  beige solid. 1H NMR (300 MHz, DMSO-d6) δ 9.21 (s, 
2H, NH2), 7.57-7.21 (m, 11H, Ar-H+benzylic-H from COOH), 5.59 (d, J = 5.3 Hz, 
1H, benzylic-H from NH2). 13C NMR (75 MHz, DMSO-d6) δ 172.3, 138.4, 138.3, 
135.6, 129.4, 128.8, 128.4, 128.3,127.4, 125.5, 57.1. 
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5.3.17 α-Phenyl(m-aminomethyl) benzoate hydrochloride (4-07). 2 drops of conc. 
Hydrochloric acid (HCl) was added to a solution of 4-02 (0.26 g, 1 mmol) in MeOH 
(3 mL) and the reaction was allowed to reflux for 1 hour. The solvent was removed 
and the sticky residue was triturated with DCM. The precipitate was filtered and 
washed with DCM to afford 4-07 (0.27 g, 97%) as a pale yellow hygroscopic solid. 
1H NMR (300 MHz, DMSO-d6) δ 9.07 (s, 3H, NH2+HCl), 8.13 (s, 1H, Ar-H), 7.96 (d, 
J =7.5 Hz, 1H, Ar-H), 7.78 (d, J = 7.9 Hz, 1H, Ar-H), 7.63-7.58 (m, 1H, Ar-H), 7.52-
7.36 (m, 5H, Ar-H), 5.81 (s, 1H, benzylic-H from NH2), 3.87 (s, 3H, methyl-H). 13C 
NMR (75 MHz, DMSO-d6) δ 165.8, 138.9, 137.7, 132.3, 130.2, 129.4, 129.1, 129.0, 








5.3.18 Methyl 3-(2-nitroguanidino)(phenyl)methyl)benzoate (MK-II-1). Using the 
procedure described for the preparation of nitroguanidino compounds and with the 
addition of 1 equivalent of TEA, MK-II-1 was obtained from 4-07 (47%) as a white 
foamy hygroscopic solid. 1H NMR (300 MHz, DMSO-d6) δ 7.90-7.87 (m, 2H, Ar-H), 
7.62-7.51 (m, 2H, Ar-H), 7.41-7.29 (m, 5H, Ar-H), 6.18 (d, J = 6.4 Hz, 1H, benzylic-
H), 3.85 (s, 3H, methyl-H). 13C NMR (75 MHz, DMSO-d6) δ 166.6, 132.4, 130.4, 
129.7, 129.3, 128.7, 128.2, 127.7, 127.5, 57.6, 52.7. IR (KBr disc) 3417, 3316, 1721, 
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1624, 1447, 1263, 751, 701 cm-1. MS (ESI) (m/z): [M + 1]+ calcd for C16H16N4O4 
329.1, found 329.1.  
 
5.3.19 (3-(Cyanomethyl)phenyl)(phenyl)methyl)-2-nitroguanidine (MK-II-2). 
Using the procedure described for the preparation of nitroguanidino compounds, MK-
II-2 was obtained from 4-05 (37%) as an off-white foamy hygroscopic solid. 1H NMR 
(300 MHz, DMSO-d6) δ 7.43-7.28 (m, 9H, Ar-H), 6.10 (d, J = 7.9 Hz, 1H, benzylic-H 
from N-H), 4.05 (s, 2H, benzylic-H from CN). 13C NMR (75 MHz, DMSO-d6) δ 
158.6, 142.6, 141.3, 131.9, 129.7, 128.0, 127.6, 127.4, 126.9, 126.6, 119.4, 57.7. IR 
(KBr disc) 3413, 3312, 2252, 1624, 1575, 1522, 1446, 1262, 702 cm-1. MS (ESI) 
(m/z): [M + 1]+ calcd for C16H15N5O2 310.1, found 310.1.  
 
5.4 L-[3H]-citrulline Assays 
5.4.1 General Methods 
All chemicals used in the assays were purchased from Sigma and were used without 
further purification unless stated otherwise. The L-[2, 3, 4, 5 -3H]-Arginine HCl and 
scintillation cocktail were purchased from Amersham. The enzymes were purchased 
from Cayman Chemicals Company. The enzymes were divided into suitable aliquots 
for each assay and they were stored at -80oC. The protocol used in this study was 
adapted with reference to Current Protocols in Pharmacology.[220] Prior to the start of 
assay, an experiment with a set of different dilutions must be performed in order to 
obtain an initial concentration-response curve. This is to determine the range of 
activity in the respective enzyme extracts from the supplier as the activity would vary 
from batch to batch produced. A maximal signal in the linear range will correspond to 
that of the optimal dose of the enzyme extract.  
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Optimization of the incubation periods for each of the enzyme isoforms were done to 
produce a linear time-activity relationship so as to ensure the consistency and 
extrapolatability of the data obtained. The incubations of nNOS and eNOS were 
carried out at 37oC, with incubation times of 15 and 20 minutes for nNOS and eNOS 
respectively. As for iNOS, it is incubated for 20 minutes at 30oC.  
It must be noted that NADPH and BH4 are both light sensitive. NADPH is especially 
unstable in solution form. Both co-factors have to be prepared fresh prior to the start 
of each assay.  
Each incubation mixture contains 125µL of drug solution, 10µL of deionized water, 
20µL of reaction buffer (350mM HEPES pH 7.4, 10 mM EDTA, 12.5 mM CaCl2, 
0.15µCi [3H]-L-arginine) and 45µL of enzyme mixture (enzyme aliquot, 5µL 20mM 
NADPH, 5µL 40 mM DTT, 5µL 400µg/ml CaM, 5µL 360µM BH4, and 25µL 50mM 
HEPES pH 7.4, freshly prepared prior to each experiment) and was incubated at the 
optimized incubation times and temperatures for the respective enzyme isoforms 
(nNOS: 15 minutes, 37oC; eNOS: 20 minutes, 37oC; iNOS, 20 minutes, 30oC). The 
reactions were initiated by the addition of the cold enzyme mixture and were 
terminated by the addition of 200 µL of stopping buffer (160 mM HEPES pH 5.5, 16 
mM EDTA) for the constitutive enzyme isoforms. Since iNOS is independent of Ca2+, 
the stopping buffer used in this case was one which contained a high concentration of 
L-Arg in place of the Ca2+ chelator (160mM HEPES pH 5.5, 80mM L-Arg). The 
reaction mixture was then passed through the Dowex-Na+ (pH < 8) column, followed 
by rinsing with 500µL of deionized water. 2mL of the scintillation cocktail was added 
to the eluent and the radioactivity was measured in counts per minute (cpm) using 
liquid scintillation counter (Perkin Elmer precisely MicroBeta TriLux 1450 LSC & 
Luminescence Counter).  
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Compounds of library MK-I and MK-II were dissolved in DMSO with a 
concentration of 100mM and subsequently diluted down to 100µM effective 
concentration for screening against the three isoforms of NOS. Only compounds III, 
IV, V, VII and X were soluble in DMSO at 100mM and were able to be prepared 
subsequently into 100µM for screening against the nNOS isoforms. Triplicates were 
done for each set of assays.  L-NNA was used as positive controls in all the assays. 
The compounds were screened at a concentration of 100µM. The analysis and 
statistical evaluation of experimental data were performed with the software Prism 3. 
The IC50 concentrations of the three isoforms of NOS were reported in the micro 
molar range (µM). 
 
 nNOS iNOS eNOS 
 IC50 ±SEM IC50 ±SEM IC50 ±SEM 
L-NNA 0.22 0.40 16.00 0.18 49.00 0.71 
Table 6: IC50 of the three isoforms (in µM) of nNOS from Cayman Chemicals 
 109 
CHAPTER 6: BIBLIOGRAPHY 
 
[1] F. A. Cotton, G. Wilkinson, C. A. Murillo, M. Bochmann, Advanced 
Inorganic Chemistry 1999, Wiley. 
[2] D. L. H. Williams, Nitrosation 1988, Cambridge University Press. 
[3] D. A. Wink, M. B. Grisham, J. B. Mitchell, P. C. Ford, Methods Enzymol 1996, 
268, 12. 
[4] J. R. Lancaster, Jr., Methods Enzymol 1996, 268, 31. 
[5] M. Hoshino, K. Ozawa, H. Seki, P. C. Ford, J. Am. Chem. Soc. 1993, 115, 
9568. 
[6] L. J. Ignarro, B. K. Barry, D. Y. Gruetter, J. C. Edwards, E. H. Ohlstein, C. A. 
Gruetter, W. H. Baricos, Biochem Biophys Res Commun 1980, 94, 93. 
[7] M. P. Doyle, J. W. Hoekstra, J Inorg Biochem 1981, 14, 351. 
[8] D. A. Wink, Y. Osawa, J. F. Darbyshire, C. R. Jones, S. C. Eshenaur, R. W. 
Nims, Arch Biochem Biophys 1993, 300, 115. 
[9] J. M. Fukuto, Adv Pharmacol 1995, 34, 1. 
[10] G. V. Buxton, C. Greenstock, W. P. Helman, A. B. Ross, J. Phys. Chem. Ref. 
Data 1988, 17, 513. 
[11] S. Padmaja, R. E. Huie, Biochem Biophys Res Commun 1993, 195, 539. 
[12] M. Feelisch, J. Cardiovasc. Pharmacol. 1991, 17, S25. 
[13] R. S. Lewis, W. M. Deen, Chem Res Toxicol 1994, 7, 568. 
[14] D. A. Wink, J. F. Darbyshire, R. W. Nims, J. E. Saavedra, P. C. Ford, Chem 
Res Toxicol 1993, 6, 23. 
[15] P. C. Ford, D. A. Wink, D. M. Stanbury, FEBS Lett 1993, 326, 1. 
[16] R. E. Huie, S. Padmaja, Free Radic Res Commun 1993, 18, 195. 
 110 
[17] J. P. Crow, J. S. Beckman, Adv Pharmacol 1995, 34, 17. 
[18] J. P. Crow, H. Ischiropoulos, Methods Enzymol 1996, 269, 185. 
[19] H. Ischiropoulos, L. Zhu, J. S. Beckman, Arch Biochem Biophys 1992, 298, 
446. 
[20] R. Bryk, D. J. Wolff, Pharmacol Ther 1999, 84, 157. 
[21] S. Moncada, A. Higgs, N Engl J Med 1993, 329, 2002. 
[22] O. W. Griffith, D. J. Stuehr, Annual Review of Physiology 1995, 57, 707. 
[23] C. Nathan, Q.-w. Xie, Cell 1994, 78, 915. 
[24] K. A. Hanafy, J. S. Krumenacker, F. Murad, Med. Sci. Monit. 2001, 7, 801. 
[25] B. S. Masters, K. McMillan, E. A. Sheta, J. S. Nishimura, L. J. Roman, P. 
Martasek, FASEB J. 1996, 10, 552. 
[26] B. Mayer, E. R. Werner, Naunyn Schmiedebergs Arch Pharmacol 1995, 351, 
453. 
[27] J. F. Kerwin, J. R. Lancaster, P. L. Feldman, J. Med. Chem. 1995, 38, 4343. 
[28] H. H. H. Schmidt, J. S. Pollock, M. Nakane, L. D. Gorsky, U. Forstermann, F. 
Murad, Proceedings of the National Academy of Sciences 1991, 88, 365. 
[29] H. H. H. W. Schmidt, F. Murad, Biochemical and Biophysical Research 
Communications 1991, 181, 1372. 
[30] H. H. H. W. Schmidt, U. Walter, Cell 1994, 78, 919. 
[31] J. S. Pollock, U. Forstermann, J. A. Mitchell, T. D. Warner, H. Schmidt, M. 
Nakane, F. Murad, Proceedings of the National Academy of Sciences 1991, 88, 
10480. 
[32] U. Forstermann, J. S. Pollock, H. H. H. Schmidt, M. Heller, F. Murad, 
Proceedings of the National Academy of Sciences 1991, 88, 1788. 
[33] J. M. Hevel, K. A. White, M. A. Marletta, J. Biol. Chem. 1991, 266, 22789. 
 111 
[34] D. J. Stuehr, H. J. Cho, N. S. Kwon, M. F. Weise, C. F. Nathan, Proceedings 
of the National Academy of Sciences 1991, 88, 7773. 
[35] Y. Yui, R. Hattori, K. Kosuga, H. Eizawa, K. Hiki, C. Kawai, J. Biol. Chem. 
1991, 266, 12544. 
[36] W. K. Alderton, C. E. Cooper, R. G. Knowles, Biochem. J. 2001, 357, 593. 
[37] R. G. Knowles, S. Moncada, Biochem J 1994, 298 ( Pt 2), 249. 
[38] D. S. Bredt, S. H. Snyder, Proceedings of the National Academy of Sciences 
1990, 87, 682. 
[39] H. J. Cho, Q. W. Xie, J. Calaycay, R. A. Mumford, K. M. Swiderek, T. D. Lee, 
C. Nathan, J. Exp. Med. 1992, 176, 599. 
[40] K. Panda, S. Ghosh, D. J. Stuehr, J. Biol. Chem. 2001, 276, 23349. 
[41] U. Siddhanta, A. Presta, B. Fan, D. Wolan, D. L. Rousseau, D. J. Stuehr, J. 
Biol. Chem. 1998, 273, 18950. 
[42] M. J. Rand, Clinical and Experimental Pharmacology and Physiology 1992, 
19, 147. 
[43] N. C. Gerber, I. Rodriguez-Crespo, C. R. Nishida, P. R. O. de Montellano, J. 
Biol. Chem. 1997, 272, 6285. 
[44] D. S. Bredt, P. M. Hwang, C. E. Glatt, C. Lowenstein, R. R. Reed, S. H. 
Snyder, Nature 1991, 351, 714. 
[45] P. Klatt, B. Heinzel, M. John, M. Kastner, E. Bohme, B. Mayer, J Biol Chem 
1992, 267, 11374. 
[46] B. Mayer, B. Heinzel, P. Klatt, M. John, K. Schmidt, E. Bohme, J Cardiovasc 
Pharmacol 1992, 20 Suppl 12, S54. 
[47] J. F. Parkinson, G. B. Philips, Fundamental and Clinical Cardiology 1997, 95. 
[48] P. L. Feldman, O. W. Griffith, D. J. Stuehr, Chem Eng News. 1993, 71, 26. 
 112 
[49] R. Iyengar, D. J. Stuehr, M. A. Marletta, Proceedings of the National Academy 
of Sciences 1987, 84, 6369. 
[50] N. S. Kwon, C. F. Nathan, C. Gilker, O. W. Griffith, D. E. Matthews, D. J. 
Stuehr, J. Biol. Chem. 1990, 265, 13442. 
[51] D. J. Stuehr, N. S. Kwon, C. F. Nathan, O. W. Griffith, P. L. Feldman, J. 
Wiseman, J. Biol. Chem. 1991, 266, 6259. 
[52] G. C. Wallace, J. M. Fukuto, J. Med. Chem. 1991, 34, 1746. 
[53] K. J. Baek, B. A. Thiel, S. Lucas, D. J. Stuehr, J Biol Chem 1993, 268, 21120. 
[54] R. T. Miller, P. Martasek, L. J. Roman, J. S. Nishimura, B. S. Masters, 
Biochemistry 1997, 36, 15277. 
[55] B. Clement, M.-H. Schultze-Mosgau, H. Wohlers, Biochemical Pharmacology 
1993, 46, 2249. 
[56] D. W. Choi, S. M. Rothman, Annu. Rev. Neurosci. 1990, 13, 171. 
[57] M. A. Dorheim, W. R. Tracey, J. S. Pollock, P. Grammas, Biochemical and 
Biophysical Research Communications 1994, 205, 659. 
[58] L. L. Thomson, H. K. Iversen, L. H. Lassen, J. Olesen, CNS Drugs 1994, 2, 
417. 
[59] K. Aisaka, S. S. Gross, O. W. Griffith, R. Levi, Biochemical and Biophysical 
Research Communications 1989, 160, 881. 
[60] D. D. Rees, R. M. J. Palmer, S. Moncada, Proceedings of the National 
Academy of Sciences 1989, 86, 3375. 
[61] A. V. Hall, H. Antoniou, Y. Wang, A. H. Cheung, A. M. Arbus, S. L. Olson, 
W. C. Lu, C. L. Kau, P. A. Marsden, J. Biol. Chem. 1994, 269, 33082. 
[62] J. E. Brenman, D. S. Chao, H. Xia, K. Aldape, D. S. Bredt, Cell 1995, 82, 743. 
[63] L. Busconi, T. Michel, J. Biol. Chem. 1993, 268
 113 
[64] J. Liu, G. Garcia-Cardena, W. C. Sessa, Biochemistry 1995, 34, 12333. 
[65] L. O. Narhi, A. J. Fulco, J. Biol. Chem. 1987, 262, 6683. 
[66] D. M. Ziegler, Drug Metab Rev 1988, 19, 1. 
[67] Y. Watanabe, J. T. Groves, Mechanism of Catalysis 1992, 20, 405. 
[68] http://structbio.vanderbilt.edu/cabp_database/general/prot_pages/calmod.html. 
[69] http://www.ebi.ac.uk/interpro/potm/2003_3/Page_1.htm. 
[70] H. Matsuda, T. Iyanagi, Biochim Biophys Acta 1999, 1473, 345. 
[71] A. Matsuoka, D. J. Stuehr, J. S. Olson, P. Clark, M. Ikeda-Saito, J. Biol. Chem. 
1994, 269, 20335. 
[72] H. M. Abu-Soud, D. J. Stuehr, Proceedings of the National Academy of 
Sciences 1993, 90, 10769. 
[73] Q. Liu, S. S. Gross, Methods Enzymol 1996, 268, 311. 
[74] S. Adak, S. Ghosh, H. M. Abu-Soud, D. J. Stuehr, J. Biol. Chem. 1999, 274, 
22313. 
[75] M. A. Noble, A. W. Munro, S. L. Rivers, L. Robledo, S. N. Daff, L. J. 
Yellowlees, T. Shimizu, I. Sagami, J. G. Guillemette, S. K. Chapman, 
Biochemistry 1999, 38, 16413. 
[76] K. A. White, M. A. Marletta, Biochemistry 1992, 31, 6627. 
[77] D. J. Stuehr, M. Ikeda-Saito, J. Biol. Chem. 1992, 267, 20547. 
[78] K. McMillan, D. S. Bredt, D. J. Hirsch, S. H. Snyder, J. E. Clark, B. S. S. 
Masters, Proceedings of the National Academy of Sciences 1992, 89, 11141. 
[79] K. McMillan, B. S. S. Masters, Biochemistry 1995, 34, 3686. 
[80] J. Wang, D. J. Stuehr, M. Ikeda-Saito, D. L. Rousseau, J. Biol. Chem. 1993, 
268, 22255. 
[81] P. F. Chen, A. L. Tsai, K. K. Wu, J. Biol. Chem. 1994, 269, 25062. 
 114 
[82] P.-F. Chen, A.-L. Tsai, V. Berka, K. K. Wu, J. Biol. Chem. 1997, 272, 6114. 
[83] R. Gachhui, D. K. Ghosh, C. Wu, J. Parkinson, B. R. Crane, D. J. Stuehr, 
Biochemistry 1997, 36, 5097. 
[84] W. K. Alderton, C. E. Cooper, R. G. Knowles, Biochem. J. 2001, 357, 593. 
[85] C. S. Raman, H. Li, P. Martasek, V. Kral, B. S. S. Masters, T. L. Poulos, Cell 
1998, 95, 939. 
[86] B. R. Crane, R. J. Rosenfeld, A. S. Arvai, G. D. K., S. Ghosh, J. A. Tainer, D. 
J. Stuehr, E. D. Getzoff, EMBO J. 1999, 18, 6271. 
[87] E. R. Werner, E. Pitters, K. Schmidt, H. Wachter, G. Werner-Felmayer, B. 
Mayer, Biochem J 1996, 320 ( Pt 1), 193. 
[88] S. Kaufman, Proceedings of the National Academy of Sciences 1963, 50, 1085. 
[89] M. A. Tayeh, M. A. Marletta, J. Biol. Chem. 1989, 264, 19654. 
[90] N. S. Kwon, C. F. Nathan, D. J. Stuehr, J. Biol. Chem. 1989, 264, 20496. 
[91] E. R. Werner, G. Werner-Felmayer, H. Wachter, Proc Soc Exp Biol Med 1993, 
203, 1. 
[92] B. Mayer, Semin. Neurosci. 1993, 197. 
[93] H. H. H. W. Schmidt, R. M. Smith, M. Nakane, F. Murad, Biochemistry 1992, 
31, 3243. 
[94] J. S. Pollock, E. R. Werner, J. A. Mitchell, U. Forstermann, Endothelium 1993, 
1, 147. 
[95] B. Mayer, M. John, B. Heinzel, E. R. Werner, H. Wachter, G. Schultz, E. 
Bohme, FEBS Letters 1991, 288, 187. 
[96] J. M. Hevel, M. A. Marletta, Biochemistry 1992, 31, 7160. 
[97] P. A. Friedman, A. H. Kappelman, S. Kaufman, J. Biol. Chem. 1972, 247, 
4165. 
 115 
[98] R. Shiman, M. Akino, S. Kaufman, J. Biol. Chem. 1971, 246, 1330. 
[99] S. Kaufman, Annu Rev Nutr 1993, 13, 261. 
[100] S. Kaufman, Adv Enzymol Relat Areas Mol Biol 1993, 67, 77. 
[101] J. Giovanelli, K. L. Campos, S. Kaufman, Proceedings of the National 
Academy of Sciences 1991, 88, 7091. 
[102] K. J. Baek, B. A. Thiel, S. Lucas, D. J. Stuehr, J. Biol. Chem. 1993, 268, 
21120. 
[103] P. Klatt, K. Schmidt, G. Uray, B. Mayer, J. Biol. Chem. 1993, 268, 14781. 
[104] E. R. Werner, M. Schmid, G. Werner-Felmayer, B. Mayer, H. Wachter, 
Biochem J 1994, 304 ( Pt 1), 189. 
[105] P. Klatt, M. Schmid, E. Leopold, K. Schmidt, E. R. Werner, B. Mayer, J. Biol. 
Chem. 1994, 269, 13861. 
[106] N. Bec, A. C. F. Gorren, C. Voelker, B. Mayer, R. Lange, J. Biol. Chem. 1998, 
273, 13502. 
[107] A. R. Hurshman, C. Krebs, D. E. Edmondson, B. H. Huynh, M. A. Marletta, 
Biochemistry 1999, 38, 15689. 
[108] T. O. Fischmann, A. Hruza, X. D. Niu, J. D. Fossetta, C. A. Lunn, E. Dolphin, 
A. J. Prongay, P. Reichert, D. J. Lundell, S. K. Narula, P. C. Weber, Nat Struct 
Biol 1999, 6, 233. 
[109] E. S. Furfine, M. F. Harmon, J. E. Paith, E. P. Garvey, Biochemistry 1993, 32, 
8512. 
[110] S. Pfeiffer, E. Leopold, K. Schmidt, F. Brunner, B. Mayer, Br J Pharmacol 
1996, 118, 1433. 
[111] N. M. Olken, M. A. Marletta, Biochemistry 1993, 32, 9677. 
 116 
[112] M. Bergmann, L. Zervas, H. Rinke, H. Z. Schleich, Physiol. Chem. 1934, 224, 
33. 
[113] P. Klatt, K. Schmidt, F. Brunner, B. Mayer, J Biol Chem 1994, 269, 1674. 
[114] E. P. Garvey, J. V. Tuttle, K. Covington, B. M. Merrill, E. R. Wood, S. A. 
Baylis, I. G. Charles, Arch Biochem Biophys 1994, 311, 235. 
[115] G. J. Southan, S. S. Gross, J. R. Vane, The Biology of Nitric Oxide 1994, 4, 4. 
[116] S. S. Gross, D. J. Stuehr, K. Aisaka, E. A. Jaffe, R. Levi, O. W. Griffith, 
Biochem Biophys Res Commun 1990, 170, 96. 
[117] P. L. Feldman, O. W. Griffith, H. Hong, D. J. Stuehr, J. Med. Chem. 1993, 36, 
491. 
[118] P. J. Shultz, L. Raij, J Clin Invest 1992, 90, 1718. 
[119] C. Frey, K. Narayanan, K. McMillan, L. Spack, S. S. Gross, B. S. Masters, O. 
W. Griffith, J Biol Chem 1994, 269, 26083. 
[120] N. E. Rogers, L. J. Ignarro, Biochem Biophys Res Commun 1992, 189, 242. 
[121] K. Narayanan, O. W. Griffith, J. Med. Chem. 1994, 37, 885. 
[122] J. C. Salerno, P. Martasek, L. J. Roman, B. S. Masters, Biochemistry 1996, 35, 
7626. 
[123] Y. Xia, L. J. Roman, B. S. Masters, J. L. Zweier, J Biol Chem 1998, 273, 
22635. 
[124] W. M. Moore, R. K. Webber, G. M. Jerome, F. S. Tjoeng, T. P. Misko, M. G. 
Currie, J Med Chem 1994, 37, 3886. 
[125] T. B. McCall, M. Feelisch, R. M. Palmer, S. Moncada, Br J Pharmacol 1991, 
102, 234. 
 117 
[126] E. S. Furfine, M. F. Harmon, J. E. Paith, R. G. Knowles, M. Salter, R. J. Kiff, 
C. Duffy, R. Hazelwood, J. A. Oplinger, E. P. Garvey, J Biol Chem 1994, 269, 
26677. 
[127] B. G. Shearer, K. W. Franzmann, H. F. Hodson, WO patent 95/00505 1995. 
[128] H. F. Hodson, R. M. J. Palmer, D. A. Sawyer, R. G. Knowles, K. W. 
Franzmann, M. J. Drysdale, S. Smith, P. I. Davies, H. A. R. Clark, B. G. 
Shearer, WO patent 95/34534. 1995. 
[129] E. A. Hallinan, S. Tsymbalov, W. M. Moore, M. G. Currie, B. S. Pitzele, 
Biology of Nitric Oxide, part 5. 1995, 10, 94. 
[130] E. A. Hallinan, F. S. Tjoeng, K. F. Fok, T. J. Hagen, M. V. Toth, S. 
Tsymbalov, B. S. Pitzele, WO patent 95/24382. 1995. 
[131] J. G. Robertson, M. S. Bernatowicz, A. M. Dhalla, B. B. Muhoberac, J. 
Yanchunas, G. R. Matsueda, J. J. Villafranca, Bioorganic Chemistry 1995, 23, 
144. 
[132] N. M. Olken, M. A. Marletta, J Med Chem 1992, 35, 1137. 
[133] F. Murad, J. F. Kerwin, L. D. Gorsky, US Patent 5478946. 1995. 
[134] F. Murad, J. F. Kerwin, L. D. Gorsky, US patent 5380945. 1995. 
[135] M. Cowart, E. A. Kowaluk, K. L. Kohlhaas, K. M. Alexander, J. F. Kerwin, 
Bioorganic & Medicinal Chemistry Letters 1996, 6, 999. 
[136] B. G. Shearer, S. Lee, K. W. Franzmann, H. A. R. White, D. C. J. Sanders, R. 
J. Kiff, E. P. Garvey, E. S. Furfine, Bioorganic & Medicinal Chemistry Letters 
1997, 7, 1763. 
[137] Y. Lee, M. A. Marletta, P. Martasek, L. J. Roman, B. S. S. Masters, R. B. 
Silverman, Bioorganic & Medicinal Chemistry 1999, 7, 1097. 
 118 
[138] J. Eustache, A. Grob, C. Lam, O. Sellier, G. Schulz, Bioorganic & Medicinal 
Chemistry Letters 1998, 8, 2961. 
[139] R. B. Silverman, H. Huang, M. A. Marletta, P. Martasek, J. Med. Chem. 1997, 
40, 2813. 
[140] H. Huang, P. Martasek, L. J. Roman, B. S. S. Masters, R. B. Silverman, J. 
Med. Chem. 1999, 42, 3147. 
[141] H. Huang, P. Martasek, L. J. Roman, R. B. Silverman, J. Med. Chem. 2000, 43, 
2938. 
[142] J. M. Hah, L. J. Roman, P. Martasek, R. B. Silverman, J. Med. Chem. 2001, 44, 
2667. 
[143] R. G. Tilton, K. Chang, K. S. Hasan, S. R. Smith, J. M. Petrash, T. P. Misko, 
W. M. Moore, M. G. Currie, J. A. Corbett, M. L. McDaniel, et al., Diabetes 
1993, 42, 221. 
[144] T. P. Misko, W. M. Moore, T. P. Kasten, G. A. Nickols, J. A. Corbett, R. G. 
Tilton, M. L. McDaniel, J. R. Williamson, M. G. Currie, Eur J Pharmacol 
1993, 233, 119. 
[145] C. C. Wu, S. J. Chen, C. Szabo, C. Thiemermann, J. R. Vane, Br J Pharmacol 
1995, 114, 1666. 
[146] H. Ruetten, G. J. Southan, A. Abate, C. Thiemermann, Br J Pharmacol 1996, 
118, 261. 
[147] G. J. Southan, C. Szabo, C. Thiemermann, Br J Pharmacol 1995, 114, 510. 
[148] M. Nakane, V. Klinghofer, J. E. Kuk, J. L. Donnelly, G. P. Budzik, J. S. 
Pollock, F. Basha, G. W. Carter, Mol Pharmacol 1995, 47, 831. 
 119 
[149] E. P. Garvey, J. A. Oplinger, G. J. Tanoury, P. A. Sherman, M. Fowler, S. 
Marshall, M. F. Harmon, J. E. Paith, E. S. Furfine, J Biol Chem 1994, 269, 
26669. 
[150] B. R. Babu, O. W. Griffith, FASEB J 1996, 10, 1399. 
[151] B. G. Shearer, S. Lee, J. A. Oplinger, L. W. Frick, E. P. Garvey, E. S. Furfine, 
J Med Chem 1997, 40, 1901. 
[152] E. P. Garvey, J. A. Oplinger, E. S. Furfine, R. J. Kiff, F. Laszlo, B. J. Whittle, 
R. G. Knowles, J Biol Chem 1997, 272, 4959. 
[153] S. J. Sup, B. G. Green, S. K. Grant, Biochem Biophys Res Commun 1994, 204, 
962. 
[154] W. M. Moore, R. K. Webber, K. F. Fok, G. M. Jerome, C. M. Kornmeier, F. S. 
Tjoeng, M. G. Currie, Bioorg Med Chem 1996, 4, 1559. 
[155] W. M. Moore, R. K. Webber, K. F. Fok, G. M. Jerome, J. R. Connor, P. T. 
Manning, P. S. Wyatt, T. P. Misko, F. S. Tjoeng, M. G. Currie, J Med Chem 
1996, 39, 669. 
[156] R. K. Webber, S. Metz, W. M. Moore, J. R. Connor, M. G. Currie, K. F. Fok, 
T. J. Hagen, D. W. Hansen, Jr., G. M. Jerome, P. T. Manning, B. S. Pitzele, M. 
V. Toth, M. Trivedi, M. E. Zupec, F. S. Tjoeng, J Med Chem 1998, 41, 96. 
[157] D. W. Hansen, Jr., K. B. Peterson, M. Trivedi, S. W. Kramer, R. K. Webber, F. 
S. Tjoeng, W. M. Moore, G. M. Jerome, C. M. Kornmeier, P. T. Manning, J. R. 
Connor, T. P. Misko, M. G. Currie, B. S. Pitzele, J Med Chem 1998, 41, 1361. 
[158] P. K. Moore, P. Wallace, Z. Gaffen, S. L. Hart, R. C. Babbedge, Br J 
Pharmacol 1993, 110, 219. 
[159] D. J. Wolff, B. J. Gribin, Arch Biochem Biophys 1994, 311, 300. 
[160] D. J. Wolff, G. A. Datto, R. A. Samatovicz, J Biol Chem 1993, 268, 9430. 
 120 
[161] H. M. Bommel, A. Reif, L. G. Frohlich, A. Frey, H. Hofmann, D. M. Marecak, 
V. Groehn, P. Kotsonis, M. La, S. Koster, M. Meinecke, M. Bernhardt, M. 
Weeger, S. Ghisla, G. D. Prestwich, W. Pfleiderer, H. H. H. W. Schmidt, J. 
Biol. Chem. 1998, 273, 33142. 
[162] L. G. Frohlich, P. Kotsonis, H. Traub, S. Taghavi-Moghadam, N. Al-Masoudi, 
H. Hofmann, H. Strobel, H. Matter, W. Pfleiderer, H. H. H. W. Schmidt, J. 
Med. Chem. 1999, 42, 4108. 
[163] E. R. Werner, H. H. H. Schmidt, Handbook Exp Pharmacol 2000, 143, 137. 
[164] P. Kotsonis, L. G. Frohlich, C. S. Raman, H. Li, M. Berg, R. Gerwig, V. 
Groehn, Y. Kang, N. Al-Masoudi, S. Taghavi-Moghadam, D. Mohr, U. 
Munch, J. Schnabel, P. Martasek, B. S. S. Masters, H. Strobel, T. Poulos, H. 
Matter, W. Pfleiderer, H. H. H. W. Schmidt, J. Biol. Chem. 2001, 276, 49133. 
[165] D. J. Stuehr, O. A. Fasehun, N. S. Kwon, S. S. Gross, J. A. Gonzalez, R. Levi, 
C. F. Nathan, FASEB J 1991, 5, 98. 
[166] H. G. Alexander, J Neuropsychiatr 1962, 3, 388. 
[167] G. A. Joly, K. Narayanan, O. W. Griffith, R. G. Kilbourn, Br J Pharmacol 
1995, 115, 491. 
[168] V. B. Schini, P. M. Vanhoutte, J. Pharmacol. Exp. Ther. 1992, 261, 553. 
[169] R. W. Lenz, R. Hart, R. L. Ax, M. J. Cormier, Gamete Research 1984, 9, 253. 
[170] M. Cimino, B. Weiss, Biochem Pharmacol 1988, 37, 2739. 
[171] L. Jousselin, Compt. rend. 1887, 85, 548. 
[172] L. Jousselin, Compt. rend. 1879, 88, 814. 
[173] G. Pellizzari, Gazz. chim. ital 1891, 21, 405. 
[174] A. P. N. Franchimont, Rec. trav. chim. 1891, 10, 231. 
[175] J. Thiele, Ann. 1892, 270, 1. 
 121 
[176] J. Thiele, Ann. 1893, 273, 133. 
[177] A. Aubertein, Mém. poudres 1948, 30, 143. 
[178] T. L. Davis, A. A. Ashdown, H. R. Couch, J. Am. Chem. Soc. 1925, 47, 1063. 
[179] M. D. Marqueyrol, P. Loriette, Swiss patent 1920, 87384. 
[180] A. Stettbacher, Nitrocellulose 1936, 7, 141. 
[181] L. Jousselin, Compt. rend. 1877, 85, 548. 
[182] T. Ewan, J. H. Young, J. Soc. Chem. Ind. 1921, 40, 109T. 
[183] G. B. L. Smith, V. J. Sabetta, O. F. Steinbach, Ind. Eng. Chem. 1931, 23, 1124. 
[184] L. Fishbein, J. A. Gallaghan, J. Am. Chem. Soc. 1954, 76, 1877. 
[185] A. F. McKay, Chemical Reviews 1952, 51, 301. 
[186] Y. K. Bong, PhD. Dissertation, NUS 2004. 
[187] A. V. Dolzhenko, W. K. Chui, A. V. Dolzhenko, Synthesis 2006, 4, 597. 
[188] A. V. Dolzhenko, A. V. Dolzhenko, Unpublished results 2007. 
[189] A. V. Dolzhenko, A. V. Dolzhenko, W. K. Chui, Proceedings of ECSOC-9, 
International Electronic Conference on Synthetic Organic Chemistry, 9th, Nov. 
1-30, 2005 2005. 
[190] A. V. Dolzhenko, A. V. Dolzhenko, W. K. Chui, Heterocycles 2007, 71, 429. 
[191] A. V. Dolzhenko, A. V. Dolzhenko, W. K. Chui, Tetrahedron 2007, 63, 12888. 
[192] B. R. Babu, C. Frey, O. W. Griffith, J Biol Chem 1999, 274, 25218. 
[193] B. R. Crane, A. S. Arvai, R. Gachhui, C. Wu, D. K. Ghosh, E. D. Getzoff, D. J. 
Stuehr, J. A. Tainer, Science 1997, 278, 425. 
[194] B. R. Crane, A. S. Arvai, D. K. Ghosh, C. Wu, E. D. Getzoff, D. J. Stuehr, J. 
A. Tainer, Science 1998, 279, 2121. 
[195] H. Li, C. S. Raman, C. B. Glaser, E. Blasko, T. A. Young, J. F. Parkinson, M. 
Whitlow, T. L. Poulos, J Biol Chem 1999, 274, 21276. 
 122 
[196] H. Li, H. Shimizu, M. Flinspach, J. Jamal, W. Yang, M. Xian, T. Cai, E. Z. 
Wen, Q. Jia, P. G. Wang, T. L. Poulos, Biochemistry 2002, 41, 13868. 
[197] B. Fan, J. Wang, D. J. Stuehr, D. L. Rousseau, Biochemistry 1997, 36, 12660. 
[198] S. J. T. Andrew M. Davis, Angewandte Chemie International Edition 1999, 38, 
736. 
[199] A. F. McKay, Picard, J. P., Brunet, P.E., Can. J. Chem. 1951, 29, 76. 
[200] A. H. Lamberton, Quart. Revs. 1951, 5, 75. 
[201] D. C. Schlegel, B. L. Zenitz, C. A. Fellows, S. C. Laskowski, D. C. Behn, D. 
K. Phillips, I. Botton, P. T. Speight, J Med Chem 1984, 27, 1682. 
[202] K. Abiraj, D. C. Gowda, Journal of Chemical Research 2003, 6, 332. 
[203] A. F. McKay, J. P. Picard, P. E. Brunet, Canadian Journal of Chemistry 1951, 
29, 746. 
[204] S. Itsuno, K. Miyazaki, K. Ito, Tetrahedron Letters 1986, 27, 3033. 
[205] M. Schlosser, Organometallics in Synthesis - A Manual 2002, John Wiley and 
Sons. 
[206] T. W. Greene, P. G. M. Wuts, Protective Groups in Organic Synthesis 1999, 
Wiley. 
[207] Y. Goldberg, C. Bensimon, H. Alper, J. Org. Chem. 1992, 57, 6374. 
[208] S. J. Angyal, Organic Reactions 1954, 8, 197. 
[209] J. J. Li, Name Reactions. A Collection of Detailed Reaction Mechanisms 2006, 
Springer. 
[210] N. P. O. P. Angelo Clerici, European Journal of Organic Chemistry 2002, 
2002, 3326. 
[211] PCT Int. Appl. 2001, WO  2001096334   
 123 
[212] D. C. Atkinson, K. E. Godfrey, B. Meek, J. F. Saville, M. R. Stillings, J. Med. 
Chem. 1983, 26, 1353. 
[213] M. Yoshioka, H. Osawa, S. Fukuzawa, Bull. Chem. Soc. Jpn. 1982, 55, 877. 
[214] B. P. Bandgar, L. B. Kunde, J. L. Thote, Synthetic Communications 1997, 27, 
1149. 
[215] A. S. Kende, P. Fludzinski, Org. Synth. 1986, 64, 104. 
[216] H. C. Brown, T. P. Stocky, J. Am. Chem. Soc. 1977, 99, 8218. 
[217] C. Doucet-Personeni, P. D. Bentley, R. J. Fletcher, A. Kinkaid, G. Kryger, B. 
Pirard, A. Taylor, R. Taylor, J. Taylor, R. Viner, I. Silman, J. L. Sussman, H. 
M. Greenblatt, T. Lewis, J. Med. Chem. 2001, 44, 3203. 
[218] J. M. Hevel, M. A. Marletta, Methods Enzymol 1994, 233, 250. 
[219] D. S. Bredt, H. H. H. Schmidt, Methods in Nitric Oxide Research 1996, 249. 
[220] J. Zhang, Current Protocols in Phamacology 1998, 2.4.1. 
[221] M. A. Marletta, J Med Chem 1994, 37, 1899. 
[222] Y. Lee, P. Martasek, L. J. Roman, B. S. Masters, R. B. Silverman, Bioorg Med 
Chem 1999, 7, 1941. 
[223] J. A. Lowe, 3rd, W. Qian, R. A. Volkmann, S. Heck, J. Nowakowski, R. 
Nelson, C. Nolan, D. Liston, K. Ward, S. Zorn, C. Johnson, M. Vanase, W. S. 
Faraci, K. A. Verdries, J. Baxter, S. Doran, M. Sanders, M. Ashton, P. Whittle, 
M. Stefaniak, Bioorg Med Chem Lett 1999, 9, 2569. 
 
 
